<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) - Smailagic, N - 2015 | Cochrane Library</title> <meta content="18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) - Smailagic, N - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010632.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) - Smailagic, N - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010632.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010632.pub2" name="dc.identifier" scheme="DOI"/> <meta content="&lt;sup&gt;18&lt;/sup&gt;F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)" name="citation_title"/> <meta content="Nadja Smailagic&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Cambridge" name="citation_author_institution"/> <meta content="Marco Vacante" name="citation_author"/> <meta content="University of Oxford, John Radcliffe Hospital" name="citation_author_institution"/> <meta content="Chris Hyde" name="citation_author"/> <meta content="University of Exeter Medical School, University of Exeter" name="citation_author_institution"/> <meta content="Steven Martin" name="citation_author"/> <meta content="University of Cambridge" name="citation_author_institution"/> <meta content="Obioha Ukoumunne" name="citation_author"/> <meta content="University of Exeter Medical School, University of Exeter" name="citation_author_institution"/> <meta content="Christos Sachpekidis" name="citation_author"/> <meta content="Hippokrateion Hospital" name="citation_author_institution"/> <meta content="christos_saxpe@yahoo.gr" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010632.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/01/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010632.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010632.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010632.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Fluorodeoxyglucose F18; *Radiopharmaceuticals; Alzheimer Disease [*diagnostic imaging]; Brain [diagnostic imaging]; Cognitive Dysfunction [complications, *diagnostic imaging]; Dementia [*diagnostic imaging]; Disease Progression; Early Diagnosis; Positron‐Emission Tomography; Sensitivity and Specificity" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010632.pub2&amp;doi=10.1002/14651858.CD010632.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="7LavyS58";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010632\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010632\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010632.pub2",title:"\u003csup\u003e18\u003c/sup\u003eF\\u2010FDG PET for the early diagnosis of Alzheimer\\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)",firstPublishedDate:"Jan 28, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010632.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010632.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010632.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010632.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010632.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010632.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010632.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010632.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010632.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010632.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4400 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010632.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-sec-0050"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-sec-0022"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-sec-0046"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/appendices#CD010632-sec-0055"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/table_n/CD010632StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/table_n/CD010632StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en"><sup>18</sup>F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Nadja Smailagic and Marco Vacante are to be considered as joint first authors of this review"><a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#CD010632-cr-0002">Nadja Smailagic</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#CD010632-cr-0003">Marco Vacante</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#CD010632-cr-0004">Chris Hyde</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#CD010632-cr-0005">Steven Martin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#CD010632-cr-0006">Obioha Ukoumunne</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information#CD010632-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Christos Sachpekidis</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information/en#CD010632-sec-0062">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 January 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010632.pub2">https://doi.org/10.1002/14651858.CD010632.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010632-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010632-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010632-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010632-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010632-abs-0001" lang="en"> <section id="CD010632-sec-0001"> <h3 class="title" id="CD010632-sec-0001">Background</h3> <p>¹⁸F‐FDFG uptake by brain tissue as measured by positron emission tomography (PET) is a well‐established method for assessment of brain function in people with dementia. Certain findings on brain PET scans can potentially predict the decline of mild cognitive Impairment (MCI) to Alzheimer’s disease dementia or other dementias. </p> </section> <section id="CD010632-sec-0002"> <h3 class="title" id="CD010632-sec-0002">Objectives</h3> <p>To determine the diagnostic accuracy of the ¹⁸F‐FDG PET index test for detecting people with MCI at baseline who would clinically convert to Alzheimer’s disease dementia or other forms of dementia at follow‐up. </p> </section> <section id="CD010632-sec-0003"> <h3 class="title" id="CD010632-sec-0003">Search methods</h3> <p>We searched the Cochrane Register of Diagnostic Test Accuracy Studies, MEDLINE, EMBASE, Science Citation Index, PsycINFO, BIOSIS previews, LILACS, MEDION, (Meta‐analyses van Diagnostisch Onderzoek), DARE (Database of Abstracts of Reviews of Effects), HTA (Health Technology Assessment Database), ARIF (Aggressive Research Intelligence Facility) and C‐EBLM (International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence‐based Laboratory Medicine) databases to January 2013. We checked the reference lists of any relevant studies and systematic reviews for additional studies. </p> </section> <section id="CD010632-sec-0004"> <h3 class="title" id="CD010632-sec-0004">Selection criteria</h3> <p>We included studies that evaluated the diagnostic accuracy of ¹⁸F‐FDG PET to determine the conversion from MCI to Alzheimer’s disease dementia or to other forms of dementia, i.e. any or all of vascular dementia, dementia with Lewy bodies, and fronto‐temporal dementia. These studies necessarily employ delayed verification of conversion to dementia and are sometimes labelled as ‘delayed verification cross‐sectional studies’. </p> </section> <section id="CD010632-sec-0005"> <h3 class="title" id="CD010632-sec-0005">Data collection and analysis</h3> <p>Two blinded review authors independently extracted data, resolving disagreement by discussion, with the option to involve a third review author as arbiter if necessary. We extracted and summarised graphically the data for two‐by‐two tables. We conducted exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver operating characteristic (ROC) space. When studies had mixed thresholds, we derived estimates of sensitivity and likelihood ratios at fixed values (lower quartile, median and upper quartile) of specificity from the hierarchical summary ROC (HSROC) models. </p> </section> <section id="CD010632-sec-0006"> <h3 class="title" id="CD010632-sec-0006">Main results</h3> <p>We included 14 studies (421 participants) in the analysis. The sensitivities for conversion from MCI to Alzheimer's disease dementia were between 25% and 100% while the specificities were between 15% and 100%. From the summary ROC curve we fitted we estimated that the sensitivity was 76% (95% confidence interval (CI): 53.8 to 89.7) at the included study median specificity of 82%. This equates to a positive likelihood ratio of 4.03 (95% CI: 2.97 to 5.47), and a negative likelihood ratio of 0.34 (95% CI: 0.15 to 0.75). Three studies recruited participants from the same Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort but only the largest ADNI study (<a href="http://Herholz 2011" target="_blank">Herholz 2011</a>) is included in the meta‐analysis. In order to demonstrate whether the choice of ADNI study or discriminating brain region (<a href="http://Ch%C3%A9telat 2003" target="_blank">Chételat 2003</a>) or reader assessment (<a href="http://Pardo 2010" target="_blank">Pardo 2010</a>) make a difference to the pooled estimate, we performed five additional analyses. At the median specificity of 82%, the estimated sensitivity was between 74% and 76%. There was no impact on our findings. In addition to evaluating Alzheimer's disease dementia, five studies evaluated the accuracy of ¹⁸F‐FDG PET for all types of dementia. The sensitivities were between 46% and 95% while the specificities were between 29% and 100%; however, we did not conduct a meta‐analysis because of too few studies, and those studies which we had found recruited small numbers of participants. Our findings are based on studies with poor reporting, and the majority of included studies had an unclear risk of bias, mainly for the reference standard and participant selection domains. According to the assessment of Index test domain, more than 50% of studies were of poor methodological quality. </p> </section> <section id="CD010632-sec-0007"> <h3 class="title" id="CD010632-sec-0007">Authors' conclusions</h3> <p>It is difficult to determine to what extent the findings from the meta‐analysis can be applied to clinical practice. Given the considerable variability of specificity values and lack of defined thresholds for determination of test positivity in the included studies, the current evidence does not support the routine use of ¹⁸F‐FDG PET scans in clinical practice in people with MCI. The ¹⁸F‐FDG PET scan is a high‐cost investigation, and it is therefore important to clearly demonstrate its accuracy and to standardise the process of ¹⁸F‐FDG PET diagnostic modality prior to its being widely used. Future studies with more uniform approaches to thresholds, analysis and study conduct may provide a more homogeneous estimate than the one available from the included studies we have identified. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010632-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010632-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010632-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010632-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010632-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010632-abs-0003" lang="en"> <h3>¹⁸F‐FDG PET scan for early prediction of developing Alzheimer’s disease or other dementia in people with mild cognitive impairment (MCI) </h3> <p><b>Background</b> </p> <p>The numbers of people with dementia and other cognitive problems are increasing globally. A diagnosis of dementia at early stage is recommended but there is no agreement on the best approach. A range of tests have been developed which healthcare professionals can use to assess people with poor memory or cognitive impairment. In this review we have focused on the ¹⁸F‐FDG PET test. </p> <p><b>Aim</b> </p> <p>We aimed to see how accurately the ¹⁸F‐FDG PET scan identified those people with MCI who would clinically convert to Alzheimer’s disease dementia or other types of dementia over a period of time. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to January 2013. We included 16 studies covering 697 participants with MCI. The studies have been published over a 14‐year period (1999 to 2013). Study sizes were small and ranged from 19 to 94 participants. Five papers have a mean age of less than 70 years. The age range in the youngest sample was 55 to 73 years and in the oldest sample was 71 to 86 years. Participants were mainly recruited from university departments, clinics or research centres. The percentage of participants with positive ¹⁸F‐FDG PET scans at baseline ranged in the included studies from 10.5% to 74% and the percentage of those participants who converted to Alzheimer’s disease dementia over a period of time ranged from 22% to 50%. Included studies reported a range of different cut‐off values used for identifying their participants with positive ¹⁸F‐FDG PET scans. </p> <p><b>Quality of the evidence</b> </p> <p>Our findings are based on studies with poor reporting. The majority of included studies had an unclear risk of bias, mainly because they did not describe in sufficient details how participants were selected and how the clinical diagnosis of Alzheimer’s disease dementia was justified. According to the assessment of the ¹⁸F‐FDG PET test domain, more than 50% of studies were of poor methodological quality. </p> <p>The main limitations of the review are poor reporting in the included studies, a lack of a widely‐accepted cut‐off value of the ¹⁸F‐FDG PET scan in people with MCI, and the marked variation in test accuracy between the included studies. </p> <p><b>Key findings</b> </p> <p>In this review, we have found that the ¹⁸F‐FDG PET scan, as a single test, lacks the accuracy to identify those people with MCI who would develop Alzheimer’s disease dementia or other forms of dementia over a period of time. Assuming a typical conversion rate of MCI to Alzheimer’s disease dementia of 38%, the findings indicate that for every 1000 ¹⁸F‐FDG PET scans, 174 cases with a negative scan will progress to Alzheimer's disease dementia and 285 with a positive scan will not. Therefore, a positive ¹⁸F‐FDG PET scan in people with MCI is of no clinical value in early prediction of developing Alzheimer's disease dementia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010632-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010632-sec-0050"></div> <h3 class="title" id="CD010632-sec-0051">Implications for practice</h3> <section id="CD010632-sec-0051"> <p>Positron emission tomography (PET) is a unique diagnostic tool, since it can assess pathophysiologic and metabolic processes before any anatomic changes have taken place. This capacity of PET could potentially lead to several future applications in dementias, and generally in the field of neurosciences. ¹⁸F‐FDG PET is becoming increasingly accepted in the diagnostic approach to Alzheimer's disease and related disorders. Moreover, <a href="./references#CD010632-bbs2-0122" title="SilvermanDH , SmallGW , ChangCY , LuCS , Kung De AburtoMA , ChenW , et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long‐term outcome. JAMA2001;286(17):2120‐7. ">Silverman 2001</a> has developed a cost‐effectiveness algorithm for assessment of geriatric patients presenting with early symptoms of cognitive decline; according to this, PET can be incorporated into the diagnostic work‐up of these patients, when the ‘standard’ diagnostic testing does not reveal an underlying cause for the cognitive decline (<a href="./references#CD010632-bbs2-0102" title="Moulin‐RomseeG , MaesA , SilvermanD , MortelmansL , VanLaereK . Cost‐effectiveness of 18F‐fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. European Journal of Neurology2005;12(4):254‐63. ">Moulin‐Romsee 2005</a>; <a href="./references#CD010632-bbs2-0122" title="SilvermanDH , SmallGW , ChangCY , LuCS , Kung De AburtoMA , ChenW , et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long‐term outcome. JAMA2001;286(17):2120‐7. ">Silverman 2001</a>; <a href="./references#CD010632-bbs2-0121" title="SilvermanDH , GambhirSS , HuangHW , SchwimmerJ , KimS , SmallGW , et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. Journal of Nuclear Medicine2002;43(2):253‐66. ">Silverman 2002</a>). </p> <p>The results of the included studies show a great deal of heterogeneity, encompassing both the values which would render the technology 'useless' and some which indicate a valuable diagnostic tool. Given the considerable variability and specificity values, the heterogeneity in the conduct and interpretation of the test, and the lack of defined thresholds for determining test positivity, the current evidence does not support the routine use of a ¹⁸F‐FDG PET scan in clinical practice. ¹⁸F‐FDG PET scan is a high‐cost investigation, and it is therefore important to clearly demonstrate its accuracy and to standardise the process of ¹⁸F‐FDG PET diagnostic modality prior to extending its use. </p> </section> <h3 class="title" id="CD010632-sec-0052">Implications for research</h3> <section id="CD010632-sec-0052"> <p>The understanding of the functions of the nervous system and the biology of its disorders remains a big challenge. The attempt to comprehend the molecular basis of such disorders, and to potentially interfere in the natural history of the disease, is not driven just by theoretical or purely scientific needs. In the coming decades the number of adults over 65 years is expected to increase dramatically. In this context, the development and application of functional diagnostic imaging modalities that have the opportunity to detect metabolic changes before any macroscopic anatomical changes take place, and furthermore can achieve this with the highest accuracy, will be pivotal in selecting those people who would be candidates and would benefit most from the application of such treatments. </p> <p>The ¹⁸F‐FDG PET represents a modality that can reflect biochemical/molecular changes before respective morphological imaging modalities detect them. PET assesses cerebral metabolism by measuring glucose utilisation with the use of the radiotracer ¹⁸F‐FDG, a glucose analogue, which is trapped in the neuronal cell after undergoing the first metabolic step of phosphorylation by hexokinase. Since neuronal activity depends on the continuous supply of energy, the assessment of glucose consumption by the cells is indicative of neuronal integrity and function. The ability of PET to serve as a biomarker of dementia has already been highlighted (<a href="./references#CD010632-bbs2-0069" title="DuboisB , FeldmanHH , JacovaC , DekoskyST , Barberger‐GateauP , CummingsJ , et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS‐ADRDA criteria. Lancet. Neurology2007;6(8):734‐46. ">Dubois 2007</a>; <a href="./references#CD010632-bbs2-0096" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , JackCR , KawasCH , et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):263‐9. [1552‐5260] ">McKhann 2011</a>). Moreover, a recent meta‐analysis demonstrated that ¹⁸F‐FDG PET is the strongest individual positive predictive biomarker of short‐term incident dementia in MCI (<a href="./references#CD010632-bbs2-0073" title="FrisoniGB , BocchettaM , ChételatG , RabinoviciGD , deLeonMJ , KayeJ , et al. Imaging markers for Alzheimer disease: which vs how. Neurology2013;81(5):487‐500. [DOI: 10.1212/WNL.0b013e31829d86e8] ">Frisoni 2013</a>). However, energy metabolism, reflected by ¹⁸F‐FDG distribution, is not a specific process. Neurodegenerative diseases are based on complex and overlapping molecular processes, and it is known that the metabolic pattern particularly seen in ADD is a complicated one, resulting from neurochemical changes, neuronal disconnection effects and neuronal cell loss, several of which are probably not detected by ¹⁸F‐FDG PET, due the non‐specific nature of ¹⁸F‐FDG (<a href="./references#CD010632-bbs2-0079" title="HoffmanJM , Welsh‐BohmerKA , HansonM , CrainB , HuletteC , EarlN , et al. FDG PET imaging in patients with pathologically verified dementia. Journal of Nuclear Medicine2000;41(11):1920‐8. ">Hoffman 2000</a>). Moreover, PET as a technique carries the inherent drawback of low spatial resolution and subsequently provides anatomical information of low accuracy in comparison with computed tomography or magnetic resonance imaging. The application of newer radiopharmaceuticals (e.g. the PET tracer ¹¹C‐PIB that specifically binds fibrillar amyloid‐beta plaques), which reflect different mechanisms that contribute to the progression from MCI to ADD and other dementias (<a href="./references#CD010632-bbs2-0063" title="BrückA , VirtaJR , KoivunenJ , KoikkalainenJ , ScheininNM , HeleniusH , et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging2013;40(10):1567‐72. ">Brück 2013</a>), and the advent of newer hybrid imaging modalities, like PET/MRI, that provide complementary anatomic, physiologic, metabolic, and functional information about the brain (<a href="./references#CD010632-bbs2-0064" title="CatanaC , DrzezgaA , HeissWD , RosenBR . PET/MRI for neurologic applications. Journal of Nuclear Medicine2012;53(12):1916‐25. ">Catana 2012</a>) could therefore significantly aid our understanding of brain pathophysiology, regarding very early neurodegeneration. </p> <p>Nevertheless, the results of the present analysis do not suggest the routine use of ¹⁸F‐FDG PET for detection of those people with MCI who will develop ADD. Our review carries some limitations, since generally, the methodological and reporting quality of all considered papers was relatively poor. Therefore, future studies with more uniform approaches to thresholds, analysis and study conduct with particular consistency in length of follow‐up may provide a more homogeneous estimate than the one that has been available from the included studies we have identified, in order to determine the exact role of ¹⁸F‐FDG PET in the diagnostic algorithm for such patients. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010632-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010632-sec-0015"></div> <div class="table" id="CD010632-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Summary of findings table</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>What is the diagnostic accuracy of ¹⁸F‐FDG PET biomarker for detecting Alzheimer's disease, and predicting progression to dementia, in people with mild cognitive impairment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Descriptive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Participant population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Participants diagnosed with MCI at baseline using any of the Petersen criteria or CDR = 0.5 or any 16 definitions included by <a href="./references#CD010632-bbs2-0091" title="MatthewsFE , StephanB , McKeithIG , BondJ , BrayneC . Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008; Vol. 56, issue 8:1424‐33. [1532‐5415] ">Matthews 2008</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Sources of referral</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0001"> <li> <p>GP surgeries or specialists or other institutions or self referral (n = 3)</p> </li> <li> <p>Not reported (n = 13)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MCI criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0002"> <li> <p>Petersen criteria (with or without CDR = 0.5 criterion) (n = 14)</p> </li> <li> <p>AAMI criteria (n = 1)</p> </li> <li> <p>Global Deterioration Scale (n = 1)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Sampling procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0003"> <li> <p>Consecutive or random (n = 3)</p> </li> <li> <p>Unclear (n = 13)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Prior testing</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The only testing prior to performing the ¹⁸F‐FDG PET scans was the application of diagnostic criteria for identifying participants with MCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Sources of recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0004"> <li> <p>University departments, clinics or research centres (n = 7)</p> </li> <li> <p>Multicentre, not specified (n = 3)</p> </li> <li> <p>Outpatient memory clinic or outpatients (sources not specified) or Geriatric, Research, Education and Medical centre (n = 3) </p> </li> <li> <p>Not reported (n = 3)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Index tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>¹⁸F‐FDG PET</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Threshold prespecified at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0005"> <li> <p>Yes (n = 6)</p> </li> <li> <p>No (n = 10)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>PET scan interpretation</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0006"> <li> <p>Combination of visual inspection and quantitative (rCGMr) evaluation (n = 12)</p> </li> <li> <p>Only visual PET scan interpretation (n = 4)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Threshold</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Almost all included studies referred to ratios of cerebral glucose metabolism (rCGMr) and not to absolute numbers. They used a range of different thresholds (different brain regions studied as potential AD areas as well as different scaling). </p> <p>Most of the studies (12/16) performed PET analysis based on the combination of visual analysis (qualitative) and rCGMr estimations (quantitative). The rest (4/16) only referred to visual PET inspections (qualitative‐only analysis). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>¹⁸F‐FDG hypometabolism regions</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Authors used brain regions that are expected to be affected by AD. In these terms, all studies involved temporo‐parietal lobes and most of them (12/16) also included the posterior cingulate metabolism in their assessment. 7 studies also involved part of the frontal lobes in their evaluations. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>For Alzheimer’s disease dementia:</p> <p> <ul id="CD010632-list-0007"> <li> <p>NINCDS‐ADRDA (n = 13)</p> </li> <li> <p>Other (n = 3)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Target condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Conversion from MCI to Alzheimer’s disease dementia or any other forms of dementia.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Prospectively well‐defined cohorts with any accepted definition of MCI (as above). 16 included studies (<b>N=697</b> participants) were identified. 3 studies included ADNI participants. Number included in analysis was <b>421</b> from 14 studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Quality concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>QUADAS‐2 scoring was challenging due to insufficient details. Poor reporting about sampling procedure led mainly to unclear risk of bias or contributed to high risk of bias in the participant selection domain. Although the reference standard was regarded as adequate to correctly classify the target condition, poor reporting on blinding of dementia assessors determined unclear risk of bias in the reference domain in most of the included studies. According to the assessment of Index test domain, more than 50% of studies were of poor methodological quality due to lack of prespecified threshold. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Limitations</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Limited investigation of heterogeneity due to insufficient number of studies. Lack of common thresholds. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases/ Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Median specificity from included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)<sup>1</sup> at median specificity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Consequences in a cohort of 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median percentage converting % (range)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missed cases<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over</p> <p>Diagnosed<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Alzheimer's disease dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>¹⁸F‐FDG PET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150/421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (54 to 90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5 (22 ‐ 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Key feature of the results:</b> </p> <p>The results of the included studies show a great deal of heterogeneity, encompassing both values which would render the technology “useless” and some which indicate a valuable diagnostic tool. The sensitivity values ranged from 25% to 100%, while the specificity values ranged from 29% to 100%. The values for both sensitivity and specificity were mainly over 80% in 7 included studies. In the remaining 7 studies those values were less than 80% or a sensitivity value higher than 80% was accompanied by a very low specificity value and vice versa. </p> <p><b>Investigation of heterogeneity:</b> </p> <p>We investigated the effects of interpretation of PET scan (combination of visual inspection and quantitative rCGMr evaluation versus those that used visual interpretation only) and use of the prespecified threshold on the test results. There was no impact on our findings. </p> <p>The remaining planned investigations (e.g. the effect of spectrum of participants, referral centres, ¹⁸F‐FDG reduction brain regions, inadequate blinding or loss to follow‐up) were not possible due to the limited number of studies available for each analysis. We conducted sensitivity analyses for type of clinical diagnosis for MCI and for type of reference standard. There was no impact on our findings. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Conclusions:</b> </p> <p>Given the considerable variability and specificity values, the heterogeneity in the conduct and interpretation of the test, and lack of defined thresholds for determination of test positivity in the included studies, the current evidence does not support the routine use of ¹⁸F‐FDG PET scan in clinical practice. ¹⁸F‐FDG PET scan is a high‐cost investigation, and it is therefore important to clearly demonstrate its accuracy and to standardise the process of ¹⁸F‐FDG PET diagnostic modality prior to its being widely used. Future studies with more uniform approaches to thresholds, analysis and study conduct may provide a more homogeneous estimate than the one that has been available from the included studies we have identified. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Meta‐analytic estimate of sensitivity derived from the HSROC model at a fixed value of specificity. We did not compute summary estimates of sensitivity and specificity because the studies that contributed to the estimation of the summary ROC curve used various thresholds. </p> <p><sup>2</sup> We derived the median proportion converting (reported as a percentage) and range using all the studies included in the analysis for each target condition. </p> <p><sup>3</sup> We computed missed and over‐diagnosed numbers using the median proportion converting to each target condition. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010632-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010632-sec-0016"></div> <p>The most common form of dementia in the general population is Alzheimer’s disease. It is useful to distinguish the term Alzheimer's disease, which refers to underlying pathology, from Alzheimer's disease dementia, which is the final stage of a clinical syndrome associated with the pathology. </p> <p>Alzheimer’s disease dementia (ADD) afflicts 5% of men and 6% of women over the age of 60 worldwide (<a href="./references#CD010632-bbs2-0080" title="World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10). available from apps.who.int/classifications/icd10/browse/2010/en.International (accessed 16th December 2012)2010. ">ICD‐10 2010</a>). The prevalence increases exponentially with age as Alzheimer’s disease dementia affects fewer than 1% of people aged 60 to 64, but 24% to 33% of those over 85 (<a href="./references#CD010632-bbs2-0072" title="FerriCP , PrinceM , BrayneC , BrodatyH , FratiglioniL , GanguliM , et al. Global prevalence of dementia: a Delphi consensus study. Lancet2005; Vol. 366, issue 9503:2112‐7. [0140‐6736] ">Ferri 2005</a>). The earliest symptoms of ADD include short‐term memory loss, a gradual decline in other cognitive abilities and behavioural changes. Cortical intracellular neurofibrillary tangles (NFT) and extracellular β‐amyloid (Aβ) plaques (<a href="./references#CD010632-bbs2-0061" title="BraakH , BraakE . Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathologica1991; Vol. 82, issue 4:239‐59. [0001‐6322] ">Braak 1991</a>) represent the neuropathological features of Alzheimer's disease dementia and are responsible for synapse dysfunction, neuronal cell loss and consequent brain atrophy (<a href="./references#CD010632-bbs2-0052" title="BallardC , GauthierS , CorbettA , BrayneC , AarslandD , JonesE . Alzheimer's disease. Lancet2011;377(9770):1019‐31. [PUBMED: 21371747] ">Ballard 2011</a>). According to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA) criteria (<a href="./references#CD010632-bbs2-0095" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34(7):939‐44. [0028‐3878] ">McKhann 1984</a>), definite Alzheimer's diseases dementia can only be diagnosed following neuropathological examination of brain tissue, obtained by biopsy or autopsy. </p> <p>Mild cognitive impairment (MCI) represents a possible intermediary condition between normal cognition and dementia (<a href="./references#CD010632-bbs2-0100" title="MorrisJC , PriceJL . Pathologic correlates of non demented aging, mild cognitive impairment, and early‐stage Alzheimer’s disease. Journal of Molecular Neuroscience2001; Vol. 17, issue 2:101‐18. [0895‐8696] ">Morris 2001</a>; <a href="./references#CD010632-bbs2-0113" title="PetersenRC , RobertsRO , KnopmanDS , BoeveBF , GedaYE , IvnikRJ , et al. Mild cognitive impairment: ten years later. Archives of Neurology2009; Vol. 66, issue 12:1447‐55. ">Petersen 2009</a>). Currently, 16 different classifications are used to define MCI (<a href="./references#CD010632-bbs2-0091" title="MatthewsFE , StephanB , McKeithIG , BondJ , BrayneC . Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008; Vol. 56, issue 8:1424‐33. [1532‐5415] ">Matthews 2008</a>). The different definitions of MCI are based on general criteria that include a cognitive complaint (self‐ or informant‐reported or both), preserved basic activities of daily living, cognitive impairment (not normal for age and education) or decline in cognition evidenced by performance on objective cognitive tasks, and absence of dementia (<a href="./references#CD010632-bbs2-0112" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004; Vol. 256, issue 3:183‐94. [1365‐2796] ">Petersen 2004</a>; <a href="./references#CD010632-bbs2-0129" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004; Vol. 256, issue 3:240‐6. [1365‐2796] ">Winblad 2004</a>). In this review MCI refers to the clinical criteria defined by Petersen and Winbald (<a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a>; <a href="./references#CD010632-bbs2-0110" title="PetersenRC , DoodyR , KurzA , MohsRC , MorrisJC , RabinsPV , et al. Current concepts in mild cognitive impairment. Archives of Neurology2001; Vol. 58, issue 12:1985‐92. ">Petersen 2001</a>; <a href="./references#CD010632-bbs2-0112" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004; Vol. 256, issue 3:183‐94. [1365‐2796] ">Petersen 2004</a>; <a href="./references#CD010632-bbs2-0129" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004; Vol. 256, issue 3:240‐6. [1365‐2796] ">Winblad 2004</a>), or the Clinical Dementia Rating (CDR) scale (CDR = 0.5) (<a href="./references#CD010632-bbs2-0099" title="MorrisJC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology; Neurology1993;43(11):2412‐4. [1526‐632X] ">Morris 1993</a>), or any of the 16 descriptions of MCI reported by <a href="./references#CD010632-bbs2-0091" title="MatthewsFE , StephanB , McKeithIG , BondJ , BrayneC . Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008; Vol. 56, issue 8:1424‐33. [1532‐5415] ">Matthews 2008</a>. </p> <p>There are four outcomes for those within an MCI population: progression to ADD, progression to another dementia, maintaining stable MCI, or recovery. An early identification of those people who would convert from MCI to ADD and other forms of dementia may improve the opportunities for early intervention and might help their carers to plan the future. However, current data in the medical literature are still not adequate to guide clinicians and researchers in understanding the progression of dementia. There is no clinical method to predict the possible conversion of people with MCI to ADD or other dementias. Studies (<a href="./references#CD010632-bbs2-0062" title="BruscoliM , LovestoneS . Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics2004; Vol. 16, issue 2:129‐40. [1041‐6102] ">Bruscoli 2004</a>; <a href="./references#CD010632-bbs2-0092" title="MattssonN , ZetterbergH , HanssonO , AndreasenN , ParnettiL , JonssonM , et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA2009;302(4):385‐93. ">Mattsson 2009</a>; <a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a>; <a href="./references#CD010632-bbs2-0113" title="PetersenRC , RobertsRO , KnopmanDS , BoeveBF , GedaYE , IvnikRJ , et al. Mild cognitive impairment: ten years later. Archives of Neurology2009; Vol. 66, issue 12:1447‐55. ">Petersen 2009</a>) indicate that an annual average of 10% to 15% of people with MCI progress to ADD. This all depends on clinical profile, settings and investigation for vascular disease. Thus, the improvement of diagnostic accuracy is critical for the management and treatment of ADD and other dementias. Research suggests that measurable change in positron emission tomography (PET), magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers occurs years in advance of the onset of clinical symptoms (<a href="./references#CD010632-bbs2-0018" title="BeckettLA , HarveyDJ , GamstA , DonohueM , KornakJ , ZhangH , et al. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimer's &amp; Dementia2010; Vol. 6, issue 3:257‐64. [1552‐5260] ">Beckett 2010</a>). This review focuses on the relation between the ¹⁸F‐2‐fluoro‐2‐deoxy‐D‐glucose (¹⁸F‐FDG)‐PET biomarker results, the brain tissue glucose metabolism at baseline, and i) ‘conversion from MCI to Alzheimer’s disease dementia’ or ii) ‘conversion from MCI to other forms of dementia’ at follow‐up. </p> <section id="CD010632-sec-0017"> <h3 class="title" id="CD010632-sec-0017">Target condition being diagnosed</h3> <p>The primary target condition is Alzheimer's disease dementia. The diagnosis is based on the exclusion of other causes of dementia through clinical, paraclinical and neuropsychological investigations criteria as indicated in the NINCDS‐ADRDA guidelines (<a href="./references#CD010632-bbs2-0095" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34(7):939‐44. [0028‐3878] ">McKhann 1984</a>). Exclusion of other diseases such as depression, hypothyroidism, and non‐Alzheimer's disease brain lesions is a fundamental part of the diagnostic process (<a href="./references#CD010632-bbs2-0095" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34(7):939‐44. [0028‐3878] ">McKhann 1984</a>). A standard diagnostic practice is based on clinical examinations and neurological and mental status examination of the patient. Moreover, the standard diagnostic practice includes caregiver or family member interviews, focusing on progressive cognitive impairments and behavioural changes associated with the disease. </p> <p>The secondary target condition is any other form of dementia, including all‐cause dementia (<a href="./references#CD010632-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD010632-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV‐TR). 4th Edition. Washington DC: American Psychiatric Association, 1994. ">APA 1994</a>), vascular dementia (<a href="./references#CD010632-bbs2-0117" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJ , MasdeuJ , GarciaJH , et al. Vascular dementia diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop. Neurology1993; Vol. 43, issue 2:250‐60. [0028‐3878] ">Román 1993</a>), dementia with Lewy bodies (<a href="./references#CD010632-bbs2-0094" title="McKeithIG . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease2006; Vol. 9, issue 3 Suppl:417‐23. [1387‐2877] ">McKeith 2006</a>), and fronto‐temporal dementia (<a href="./references#CD010632-bbs2-0090" title="The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry1994;57(4):416‐8. ">Lund Manchester 1994</a>; <a href="./references#CD010632-bbs2-0104" title="NearyD , SnowdenJS , GustafsonL , PassantU , StussD , BlackS , et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology1998; Vol. 51, issue 6:1546‐54. [0028‐3878] ">Neary 1998</a>). </p> </section> <section id="CD010632-sec-0018"> <h3 class="title" id="CD010632-sec-0018">Index test(s)</h3> <p>PET represents a unique, minimally invasive diagnostic nuclear medicine modality of well‐documented accuracy. It assesses pathophysiologic and chemical processes by using radiopharmaceuticals that mimic endogenous molecules. Depending on the distribution of the radiotracer in the human body, images are produced and diagnostic information is acquired. Kinetic information may also be available. ¹⁸F‐FDG is the most common molecular imaging biomarker used in PET. In particular, ¹⁸F‐FDG is a radiolabeled glucose analogue and thus by entering the glucose metabolic pathway provides information about tissue metabolism. In other words, ¹⁸F‐FDG is an indicator of intracellular glucose metabolism. It has a wide variety of applications in neurosciences, oncology, and cardiology. </p> <p>¹⁸F‐FDG uptake by brain tissue as measured by PET is a well‐established method for evaluation of brain function and it has been used in the study of dementia for more than three decades. ¹⁸F‐FDG PET evaluates the regional cerebral metabolic rate for glucose (rCGMr), thus giving information about the entity of neuronal loss or synapse dysfunction The key finding is the reduced brain glucose metabolism that is associated with neurodegenerative diseases. Glucose metabolism imaging with ¹⁸F‐FDG is the most sensitive and specific imaging modality available today for the diagnosis of ADD (<a href="./references#CD010632-bbs2-0089" title="LucignaniG , FrostJF . Neurochemical imaging with emission tomography: Clinical applications. link.springer.com/chapter/10.1007/3‐540‐30005‐8_2#page‐1Diagnostic nuclear medicine (accessed January 12 2015) 2006. ">Lucignani 2006</a>). Furthermore, ¹⁸F‐FDG PET is nowadays considered an imaging biomarker for Alzheimer's disease before onset of dementia and in clinical trials (<a href="./references#CD010632-bbs2-0057" title="BohnenNI , DjangDSW , HerholzK , AnzaiY , MinoshimaS . Effectiveness and safety of 18F‐FDG PET in the evaluation of dementia: a review of the recent literature. Journal of Nuclear Medicine2012;53(1):59‐71. ">Bohnen 2012</a>; <a href="./references#CD010632-bbs2-0070" title="DuboisB , FeldmanHH , JacovaC , CummingsJL , DeKoskyST , Barberger‐GateauP , et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet. Neurology2010;9(11):1118‐27. [1474‐4422] ">Dubois 2010</a>; <a href="./references#CD010632-bbs2-0075" title="HampelH , FrankR , BroichK , TeipelSJ , KatzRG , HardyJ , et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. National Reviews. Drug Discovery2010;9(7):560‐74. ">Hampel 2010</a>). Hypometabolism in the temporo‐parietal lobe, as assessed by qualitative visual interpretation of the PET scan, represents the typical pattern found in ADD (<a href="./references#CD010632-bbs2-0078" title="HerholzK , SalmonE , PeraniD , BaronJ , HolthoffV , FrölichL , et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage2002; Vol. 17, issue 1:302‐16. [1053‐8119] ">Herholz 2002</a>; <a href="./references#CD010632-bbs2-0105" title="NitriniR , BuchpiguelC , CaramelliP , BahiaV , MathiasS , NascimentoC , et al. SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion. Acta Neurologica Scandinavica2000; Vol. 101, issue 3:172‐6. [1600‐0404] ">Nitrini 2000</a>). Moreover, it has been demonstrated that progression of neurodegenerative changes in people with ADD and other dementias is associated with both more cognitive impairment and larger PET metabolic deficits (<a href="./references#CD010632-bbs2-0068" title="DuaraR , GradyC , HaxbyJ , SundaramM , CutlerN , HestonL , et al. Positron emission tomography in Alzheimer's disease. Neurology1986; Vol. 36, issue 7:879‐87. [0028‐3878] ">Duara 1986</a>; <a href="./references#CD010632-bbs2-0076" title="HaxbyJV , GradyCL , DuaraR , SchlageterN , BergG , RapoportSI . Neocortical metabolic abnormalities precede non memory cognitive defects in early Alzheimer's‐type dementia. Archives of Neurology1986; Vol. 43, issue 9:882. ">Haxby 1986</a>). </p> <p>The ¹⁸F‐FDG PET pattern for MCI is not so consistent, which is unsurprising, due to the variable physical history of the disorder. However, people with MCI usually present on PET with mild global and regional hypometabolism (<a href="./references#CD010632-bbs2-0101" title="MosconiL . FDG PET in the evaluation of mild cognitive impairment and early dementia. In: SilvermanD editor(s). PET in the Evaluation of Alzheimer's Disease and Related Disorders. Springer, 2009:49‐65. [0387764194] ">Mosconi 2009</a>). ¹⁸F‐FDG PET studies have found characteristic and progressive cerebral metabolic rate for glucose (CMRgl) reductions in posterior cingulate, precuneus, parietal, temporal and frontal regions in both ADD and in people with MCI, with the findings being more pronounced in those with MCI who eventually converted to ADD (<a href="./references#CD010632-bbs2-0020" title="ChenK , LangbaumJB , FleisherAS , AyutyanontN , ReschkeC , LeeW , et al. Twelve‐month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre‐defined statistical region‐of‐interest: findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage2010; Vol. 51, issue 2:654‐64. [1053‐8119] ">Chen 2010</a>; <a href="./references#CD010632-bbs2-0042" title="MorbelliS , PiccardoA , VillavecchiaG , DessiB , BrugnoloA , PicciniA , et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel‐based MRI and FDG‐PET study. European Journal of Nuclear Medicine and Molecular Imaging2010;37(1):36‐45. [1619‐7070] ">Morbelli 2010</a>; <a href="./references#CD010632-bbs2-0108" title="PattersonJC , LilienDL , TakalkarA , PinkstonJB . Early detection of brain pathology suggestive of early AD using objective evaluation of FDG‐PET scans. International Journal of Alzheimer's Disease2010; Vol. 2011:ii. 946590. [DOI: 10.4061/2011/946590] ">Patterson 2010</a>). Moreover, a growing body of ¹⁸F‐FDG PET studies have been carried out specifically in order to evaluate the correlation between glucose metabolism impairment and the progression from MCI to ADD and other dementias. These studies suggest that certain findings on brain PET scans can potentially predict the decline of MCI to ADD. In agreement with this, a recent meta‐analysis points out that people converting from MCI, in comparison with those who did not convert to ADD, showed hypometabolism/hypoperfusion in the parietal lobe (<a href="./references#CD010632-bbs2-0120" title="SchroeterML , SteinT , MaslowskiN , NeumannJ . Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta‐analysis involving 1351 patients. NeuroImage2009; Vol. 47, issue 4:1196‐206. [1053‐8119] ">Schroeter 2009</a>). Further, <a href="./references#CD010632-bbs2-0087" title="LaforceRJr , ButeauJP , PaquetN , VerretL , HoudeM , BouchardRW . The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. American Journal of Alzheimer's Disease and Other Dementias2010;25(4):324‐32. ">Laforce 2010</a> studied the role of ¹⁸F‐FDG PET in the diagnosis of atypical/unclear dementias in a cohort of 94 people suffering from MCI or dementia. Their results showed that PET significantly reduced the percentage of unclear dementia diagnoses from 39% to 16%. </p> <p>The mainstay in ¹⁸F‐FDG PET interpretation is the visual reading of the scan, which depends heavily on the experience and previous training of the reading physician. This reliance on the observer’s qualitative interpretation and the lack of well‐defined thresholds for differentiation of pathological from normal scans is an issue regarding the application of the modality in the diagnostic work‐up of people with MCI. Nevertheless, the development and utilisation in recent years of new software tools for image analysis have helped in the direction of carrying out many brain ¹⁸F‐FDG PET studies. These software applications, some of which are currently Food and Drug Administration (FDA)‐approved, have enabled the quantification of brain PET scans, achieving objective evaluation and thus increasing the physician's interpretative confidence. Although subjective (visual) interpretation of the brain scan is the general standard in clinical practice, the addition of quantitative information can be crucial in such studies, since it improves the diagnostic accuracy (<a href="./references#CD010632-bbs2-0108" title="PattersonJC , LilienDL , TakalkarA , PinkstonJB . Early detection of brain pathology suggestive of early AD using objective evaluation of FDG‐PET scans. International Journal of Alzheimer's Disease2010; Vol. 2011:ii. 946590. [DOI: 10.4061/2011/946590] ">Patterson 2010</a>). </p> </section> <section id="CD010632-sec-0019"> <h3 class="title" id="CD010632-sec-0019">Clinical pathway</h3> <p>Dementia develops over a trajectory of several years. There is a presumed period when people are asymptomatic, and when pathology is accumulating. Individuals or their relatives may then notice subtle impairments of recent memory. Gradually, more cognitive domains become involved, and difficulty in planning complex tasks becomes increasingly apparent. In the UK, people usually present to their general practitioner, who may administer some neuropsychological tests, and will potentially refer them to a hospital memory clinic. However, many people with dementia do not present until much later in the disorder and will follow a different pathway to diagnosis, for example being identified during an admission to a general hospital for a physical illness. Thus the pathway influences the accuracy of the diagnostic test. The accuracy of the test will vary with the experience of the administrator, and the accuracy of the subsequent diagnosis will vary with the history of referrals to the particular healthcare setting. Diagnostic assessment pathways may vary between countries and diagnoses may be made by a variety of specialists including neurologists and geriatricians.  </p> <section id="CD010632-sec-0020"> <h4 class="title">Alternative test(s)</h4> <p>We are not including alternative tests in this review because there are currently no standard practice tests available for the diagnosis of dementia.  </p> <p>The Cochrane Dementia and Cognitive Improvement Group (CDCIG) is in the process of conducting a series of diagnostic test accuracy reviews of biomarkers and scales (see list below). Although we are conducting reviews on individual tests compared to a reference standard, we plan to compare our results in an overview. </p> <p> <ul id="CD010632-list-0008"> <li> <p>¹¹C‐PIB PET( Pittsburgh Compound‐B positron emission tomography)</p> </li> <li> <p>CSF (Cerebrospinal fluid analysis of abeta and tau)</p> </li> <li> <p>sMRI (structural magnetic resonance imaging)</p> </li> <li> <p>Neuropsychological tests (MMSE; Mini‐Cog; MoCA)</p> </li> <li> <p>Informant interviews (IQCODE; AD8)</p> </li> <li> <p>APOE ϵ4 (apolipoprotein ϵ4 allele gene)</p> </li> <li> <p>rCBF SPECT (regional cerebral blood flow single photon emission computerised tomography)</p> </li> </ul> </p> </section> </section> <section id="CD010632-sec-0021"> <h3 class="title" id="CD010632-sec-0021">Rationale</h3> <p>According to the latest revised NINCDS‐ADRA diagnostic criteria for ADD of the National Institute on Aging and Alzheimer Association (<a href="./references#CD010632-bbs2-0049" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):270‐9. [1552‐5260] ">Albert 2011</a>; <a href="./references#CD010632-bbs2-0070" title="DuboisB , FeldmanHH , JacovaC , CummingsJL , DeKoskyST , Barberger‐GateauP , et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet. Neurology2010;9(11):1118‐27. [1474‐4422] ">Dubois 2010</a>; <a href="./references#CD010632-bbs2-0096" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , JackCR , KawasCH , et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):263‐9. [1552‐5260] ">McKhann 2011</a>; <a href="./references#CD010632-bbs2-0124" title="SperlingRA , AisenPS , BeckettLA , BennettDA , CraftS , FaganAM , et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011; Vol. 7, issue 3:280‐92. [1552‐5260] ">Sperling 2011</a>), the confidence in diagnosing MCI due to Alzheimer's disease is raised with the application of biomarkers based on imaging or CSF measures. These tests, added to core clinical criteria, might increase the sensitivity or specificity of a testing strategy. However, it is crucial that each of these biomarkers is assessed for their diagnostic accuracy before they are adopted as routine add‐on tests in clinical practice. </p> <p>The ¹⁸F‐FDG PET biomarker, as the extra diagnostic criterion, might facilitate accurate identification of those people with MCI who would convert to ADD or other forms of dementia. At the present time there is no 'cure' for dementia, but there are some treatments which can slow cognitive and functional decline, or reduce the associated behavioural and psychiatric symptoms of dementia (<a href="./references#CD010632-bbs2-0056" title="BirksJ . Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD005593] ">Birks 2006</a>; <a href="./references#CD010632-bbs2-0097" title="McShaneR , Areosa SastreA , MinakaranN . Memantine for dementia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD003154.pub5] ">McShane 2006</a>). In addition, the accurate early diagnosis of dementia may improve opportunities for the use of newly‐evolving interventions designed to delay or prevent progression to more debilitating stages of dementia (<a href="./references#CD010632-bbs2-0106" title="OddoS , BillingsL , KesslakJP , CribbsDH , LaFerlaFM . Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron2004; Vol. 43, issue 3:321‐32. ">Oddo 2004</a>). Coupled with appropriate contingency planning, proper recognition of the disease may also help to prevent inappropriate and potentially harmful admissions to hospital or institutional care (<a href="./references#CD010632-bbs2-0103" title="National Audit Office. Improving Services and Support for People with Dementia. www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf2007. ">NAO 2007</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010632-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010632-sec-0022"></div> <p>To determine the diagnostic accuracy of the ¹⁸F‐FDG‐PET index test for detecting people with MCI at baseline who would clinically convert to ADD or other forms of dementia at follow‐up. Although we want to identify whether 'early forms of Alzheimer's disease dementia' are present at the moment of examination, there is no reference standard to make a final diagnosis of early ADD. Follow‐up is therefore needed to reconstruct what was going on at the time of the index examination. In this context, it is clear that the duration of follow‐up becomes critical, i.e. sufficiently long to capture the natural course of conversion. </p> <section id="CD010632-sec-0023"> <h3 class="title" id="CD010632-sec-0023">Secondary objectives</h3> <p>To investigate heterogeneity of test accuracy in the included studies.</p> <p>We expect that heterogeneity will be likely and that it will be an important component of the review. The potential sources of heterogeneity, which we will use as a framework for the investigation of heterogeneity, include target population, index test, target disorder and study quality. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010632-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010632-sec-0024"></div> <section id="CD010632-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010632-sec-0026"> <h4 class="title">Types of studies</h4> <p>We consider longitudinal cohort studies in which index test results are obtained at baseline and the reference standard results at follow‐up (see below for detail about the nature of the index test and reference standard). These studies necessarily employ delayed verification of conversion to dementia and are sometimes labelled as ‘delayed verification cross‐sectional studies’ (<a href="./references#CD010632-bbs2-0058" title="BossuytPM , ReitsmaJB , BrunsDE , GatsonisCA , GlasziouPP , IrwigLM , et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Family Practice2004;21(1):4‐10. [0263‐2136] ">Bossuyt 2004</a>; <a href="./references#CD010632-bbs2-0059" title="BossuytPM , LeeflangMM . Developing criteria for including studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Chapter 6. Version 0.4. srdta.cochrane.org/sites/srdta.cochrane.org/files/uploads/Chapter06‐Including‐Studies%20%28September‐2008%29.pdf2008. ">Bossuyt 2008</a>; <a href="./references#CD010632-bbs2-0086" title="KnottnerusJA , VanWeelC , MurisJWM . Evaluation of diagnostic procedures. BMJ2002; Vol. 324, issue 7335:477‐80. [0959‐8138] ">Knottnerus 2002</a>).  </p> <p>We also consider case‐control studies if they incorporate a delayed verification design. This occurs in the context of a cohort study, so these studies are invariably diagnostic nested case‐control studies. W<i>e</i> only include data on performance of the index test to discriminate between people with MCI who convert to dementia and those who remained stable from those studies. We have not considered data from healthy controls or any other control group. </p> </section> <section id="CD010632-sec-0027"> <h4 class="title">Participants</h4> <p>Participants recruited and clinically classified as those with MCI at baseline were eligible for this review. We include studies that used the Petersen or revised Petersen criteria (<a href="http://archie.cochrane.org/sections/documents/view?version=z1301140549136504479855969294619%26format=REVMAN#REF-Petersen-1999" target="_blank">Petersen 1999</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1301140549136504479855969294619%26format=REVMAN#REF-Petersen-2004" target="_blank">Petersen 2004</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1301140549136504479855969294619%26format=REVMAN#REF-Winblad-2004" target="_blank">Winblad 2004</a>) or the Clinical Dementia Rating (CDR = 0.5) scale (<a href="http://archie.cochrane.org/sections/documents/view?version=z1301140549136504479855969294619%26format=REVMAN#REF-Morris-1993" target="_blank">Morris 1993</a>) or any of the 16 different classifications of MCI described by <a href="http://archie.cochrane.org/sections/documents/view?version=z1301140549136504479855969294619%26format=REVMAN#REF-Matthews-2008" target="_blank">Matthews 2008</a> as diagnostic criteria for MCI. Those criteria are presented in <a href="#CD010632-tbl-0002">Table 1</a> and <a href="#CD010632-tbl-0003">Table 2</a>. </p> <div class="table" id="CD010632-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classification systems for describing mild cognitive impairment according to Matthews 2008</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>System</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impairment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Age‐related cognitive change</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ACMI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age‐consistent memory</p> <p>impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memories aging in accord with normative expectations; individual aged 50 to 79 and reports a decline in memory verified using objective memory testing performance (within ± 1 standard deviation of aged norms on 75% of tests (memory) administered); preserved general functioning. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ARCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age‐related cognitive decline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objectively identified decline in memory and cognitive functioning considered to be a normal consequence of aging. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Category systems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective memory complaint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐reported decline in memory.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mini‐Mental State Examination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Classification based on MMSE cut‐offs (maximum score 30). 'Normal' defined as a score from 27 to 30; MCI defined as a score from 22 to 26; and 'impaired' defined as a score &lt; 21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Pathological decline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MNCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild neurocognitive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impairment resulting from a general medical condition; reported decline in cognitive functioning supported by formal testing; deficits observed in at least 2 areas of cognitive functioning; interference in social, occupational, or other areas of functioning. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIND</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive impairment no dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive impairment in one or more domains (including memory and non‐memory domains) that can have a variety of aetiologies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benign senescent</p> <p>Forgetfulness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impairment in remote memory and intact recent memory; awareness of the impairment and use of compensatory </p> <p>strategies.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AAMI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age‐associated memory impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective and objective memory loss associated with normal aging; individual aged 50 and older and shows adequate intellectual function (i.e. without dementia). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimal dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive impairment in memory and minor and variable errors in orientation; no evidence of impaired occupational or social functioning; self care unimpaired. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited cognitive disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported decline in memory with use of compensatory strategies; occasional forgetfulness (e.g. names, places); 1 or 2 errors on cognitive (memory) testing. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionable dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impaired memory and non‐memory test performance; no significant activity of daily living or instrumental activity of daily living interference. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AACD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age‐associated cognitive decline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐ or informant report of cognitive decline (gradual and present for 6 months); objective difficulties in any of the following domains: learning and memory, attention and concentration, thinking, language, and visuospatial functioning </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild cognitive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decline in cognitive performance, including memory impairment and learning or concentration difficulties; complaint confirmed by cognitive tests; may precede, accompany, or follow a wide variety of infections or physical disorders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Mayo Clinic Criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N‐MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amnestic mild cognitive impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective memory complaint; normal general cognitive function; normal range of activities of daily living; objective impairment in 1 or more domains other than memory. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>A‐MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amnestic mild cognitive impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective memory complaint; normal general cognitive function; normal range of activities of daily living; impaired memory performance; normal non‐memory test performance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>M‐MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple mild cognitive impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective memory complaint; normal general cognitive function; normal range of activities of daily living; impaired memory and nonmemory test performance </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010632-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for the diagnosis of mild cognitive impairment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Petersen 1999</b> </p> <p> <ol id="CD010632-list-0009"> <li> <p>Memory complaint, preferably corroborated by an informant.</p> </li> <li> <p>Impaired memory function compared for age and education.</p> </li> <li> <p>Preserved general cognitive function.</p> </li> <li> <p>Intact activities of daily living.</p> </li> <li> <p>Not demented.</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Petersen 2004</b> </p> <p> </p> <p>4 subtypes of MCI were identified:</p> <p> <ol id="CD010632-list-0010"> <li> <p>Amnesic mild cognitive impairment, single domain – isolated memory impairment of more than 1.0 SD compared with the age‐ and education‐specific norms, and no difficulty in any other area of cognitive functioning. </p> </li> <li> <p>Amnesic mild cognitive impairment, multiple domain – 2 or more cognitive domains are impaired, 1 of which is memory impairment (impairment of more than 1.0 SD below the mean of the respective age‐ and education‐matched population). </p> </li> <li> <p>Non‐amnesic mild cognitive impairment, single domain – impairment in a single domain other than memory of more than 1.0 SD. </p> </li> <li> <p>Non‐amnesic mild cognitive impairment, multiple domains – impairments in 2 or more domains of more than 1.0 SD but no memory impairment. </p> </li> </ol> </p> <p> </p> <p>All 4 subtypes of mild cognitive impairment also have to meet the following criteria:</p> <p>a)  the presence of a complaint about memory – participants or informants (or both) reporting memory impairment. </p> <p>b)  intact ability to perform activities of daily living – forgetfulness not compromising overall functional ability; impairment owing to physical disease not sufficient for exclusion. </p> <p>c)   absence of dementia – assessed by DSM–IV criteria.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morris 1993</b> </p> <p> </p> <p>Clinical Dementia Rating (CDR) is a scale used to classify patients along a continuum from normal aging through Alzheimer’s disease. This scale describes a continuum from normal (CDR 0) through questionable dementia or MCI (CDR 0.5) to mild (CDR 1), moderate (CDR 2), and severe (CDR 3) dementia. </p> <p> </p> <p>Patient's cognitive and functional performances are assessed in 6 areas: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Scores in each of these areas are combined to obtain the total score. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MCI: mild cognitive impairment</p> </div> </div> <p>We exclude those studies that involve people with MCI possibly caused by: i) current use or history of alcohol/drug abuse; ii) Central Nervous System trauma (e.g. subdural haematoma), tumour or infection; iii) other neurological conditions e.g. Parkinson’s or Huntington’s diseases. </p> </section> <section id="CD010632-sec-0028"> <h4 class="title">Index tests</h4> <p><b>¹⁸F‐FDG PET biomarker test</b> </p> <p>There are currently no generally accepted standards for a ¹⁸F‐FDG positivity threshold, and therefore we have used the criteria which were applied in each included primary study to classify participants as either ¹⁸F‐FDG‐positive or ¹⁸F‐FDG‐negative, according to the degree of glucose metabolism in selected brain regions. Some studies apply a qualitative assessment of PET scans, while some apply both qualitative and quantitative assessments. Moreover, different thresholds are used in quantitative studies. While this may generate heterogeneity it should be noted that the addition of quantitative analysis (in the interpretation of the ¹⁸F‐FDG PET brain scan) in clinical practice is done in order to support the visual (qualitative) reading of the scan by the physician. </p> <p>A range of thresholds have been used in primary research, for instance: i) "the regional cerebral glucose metabolism ratio (rCGM‐r) is lower than 80% of whole brain mean of control subjects" (<a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. ">Chételat 2003</a>); ii) "the rCGM‐r of temporo‐parietal and posterior cingulate &lt; 1.3 ‐ 8" (<a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. ">Anchisi 2005</a>). </p> <p>We considered the use of any image analysis technique, ¹⁸F‐FDG injection dose, the time between ¹⁸F‐FDG injection and PET acquisition, and ¹⁸F‐FDG reduction regions (e.g. parietal, temporal, frontal lobes, posterior cingulated, precuneus). The exact administered ¹⁸F‐FDG activity does not affect the PET examination (as long as it ranges between the accepted limits for acquiring proper images), as this can be compensated for by the duration of the scan; the number of counts detected by the scanner is the key finding. </p> <p>The accepted limits of administered activity are defined by guidelines published by the Nuclear Medicine Societies. The two major ones are the Society of Nuclear Medicine (SNM, USA) (<a href="./references#CD010632-bbs2-0127" title="WaxmanA , HerholzK , LewisD , HerscovitchP , MinoshimaS , IchiseM , et al. Society of Nuclear Medicine procedure guideline for FDG PET brain imaging. interactive.snm.org/docs/FDG_brain_perfusion_V0%203%20(10‐1)%20Final.pdf (accessed 12th January 2015) 2009. ">Waxman 2009</a>) and the European Association of Nuclear Medicine (EANM, Europe) (<a href="./references#CD010632-bbs2-0125" title="VarroneA , AsenbaumS , Vander BorghtV , BooijJ , NobiliF , NågrenK , et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging2009;36(12):2103‐10. ">Varrone 2009</a>). According to SNM, the recommended ¹⁸F‐FDG activity in adults for brain PET is 185 ‐ 740 MBq (or 5 ‐ 20 mCi). According to EANM, the recommended administered activity for adults is 300 – 600 MBq (typically 370 MBq) in 2D mode and 125 – 250 MBq (typically 150 MBq) in 3D mode. All studies included in this review demonstrated homogeneity in the protocol followed, with no substantial differences, regarding administered dose or scanning acquisition followed. Moreover, despite the between‐studies differences regarding interpretation criteria, the evaluation of the PET scans was based on the fundamental principle of detection of a pattern of brain hypometabolism (decreased ¹⁸F‐FDG uptake) in people with MCI that is topographically consistent with the respective hypometabolic pattern expected to be seen in ADD. This means detection of regional metabolic reductions mainly in the temporo‐parietal and posterior cingulate cortices. </p> <p>The differences in exact timing of image acquisition also do not influence the study, as long as the acquisition does not start earlier than 30 minutes after ¹⁸F‐FDG injection. It is recommended, however, that each department follow a standard protocol with a fixed time for starting the acquisition (e.g. 30 or 60 minutes after injection) (<a href="./references#CD010632-bbs2-0125" title="VarroneA , AsenbaumS , Vander BorghtV , BooijJ , NobiliF , NågrenK , et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging2009;36(12):2103‐10. ">Varrone 2009</a>; <a href="./references#CD010632-bbs2-0127" title="WaxmanA , HerholzK , LewisD , HerscovitchP , MinoshimaS , IchiseM , et al. Society of Nuclear Medicine procedure guideline for FDG PET brain imaging. interactive.snm.org/docs/FDG_brain_perfusion_V0%203%20(10‐1)%20Final.pdf (accessed 12th January 2015) 2009. ">Waxman 2009</a>). The aim of the acquisition is the good contrast between grey and white matter. </p> <p>We did not include any comparator test because there are currently no standard practice tests available for the diagnosis of dementia. We compared the index test with a reference standard. </p> </section> <section id="CD010632-sec-0029"> <h4 class="title">Target conditions</h4> <p>There are two target conditions in this review:</p> <p>1. Alzheimer’s disease dementia (conversion from MCI to Alzheimer’s disease dementia);</p> <p>2. Other forms of dementia (conversion from MCI to other forms of dementia, i.e. any or all of vascular dementia, dementia with Lewy bodies, or fronto‐temporal dementia). </p> </section> <section id="CD010632-sec-0030"> <h4 class="title">Reference standards</h4> <p>For the purpose of this review, several definitions of ADD are acceptable. We Included studies that applied probable or possible NINCDS‐ADRDA criteria (<a href="./references#CD010632-bbs2-0095" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34(7):939‐44. [0028‐3878] ">McKhann 1984</a>). We also considered those studies that used the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) (<a href="./references#CD010632-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD010632-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV‐TR). 4th Edition. Washington DC: American Psychiatric Association, 1994. ">APA 1994</a>) and <i>International Classification of Diseases</i> (ICD) (<a href="./references#CD010632-bbs2-0080" title="World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10). available from apps.who.int/classifications/icd10/browse/2010/en.International (accessed 16th December 2012)2010. ">ICD‐10 2010</a>) definitions for ADD. </p> <p>Similarly, differing clinical definitions of other dementias are acceptable. For Lewy body dementia the reference standard is the McKeith criteria (<a href="./references#CD010632-bbs2-0093" title="McKeithI , GalaskoD , KosakaK , PerryE , DicksonD , HansenLA , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop. Neurology1996; Vol. 47, issue 5:1113‐24. [0028‐3878] ">McKeith 1996</a>; <a href="./references#CD010632-bbs2-0094" title="McKeithIG . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease2006; Vol. 9, issue 3 Suppl:417‐23. [1387‐2877] ">McKeith 2006</a>). For fronto‐temporal dementia the reference standards are the Lund criteria (<a href="./references#CD010632-bbs2-0090" title="The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry1994;57(4):416‐8. ">Lund Manchester 1994</a>), <a href="./references#CD010632-bbs2-0104" title="NearyD , SnowdenJS , GustafsonL , PassantU , StussD , BlackS , et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology1998; Vol. 51, issue 6:1546‐54. [0028‐3878] ">Neary 1998</a>, <a href="./references#CD010632-bbs2-0060" title="BoxerAL , MillerBL . Clinical features of frontotemporal dementia. Alzheimer Disease and Associated Disorders2005; Vol. 19, issue Suppl 1:S3‐6. [0893‐0341] ">Boxer 2005</a>, DSM‐III (<a href="./references#CD010632-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington DC: American Psychiatric Association, 1987. ">APA 1987</a>), DSM‐IV (<a href="./references#CD010632-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV‐TR). 4th Edition. Washington DC: American Psychiatric Association, 1994. ">APA 1994</a>), ICD‐9 (<a href="./references#CD010632-bbs2-0081" title="World Health Organization. Statistical Classification of Diseases and Related Health Problems 9th Revision (ICD‐9). 6th Edition. Vol. Hospital edition, vols. 1, 2, 3, Los Angeles, CA: Practice Management Information Corporation (PMIC), 2006. ">ICD‐9 2006</a>), ICD‐10 (<a href="./references#CD010632-bbs2-0080" title="World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10). available from apps.who.int/classifications/icd10/browse/2010/en.International (accessed 16th December 2012)2010. ">ICD‐10 2010</a>). For vascular dementia the reference standards are the NINDS‐ARIEN criteria (<a href="./references#CD010632-bbs2-0117" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJ , MasdeuJ , GarciaJH , et al. Vascular dementia diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop. Neurology1993; Vol. 43, issue 2:250‐60. [0028‐3878] ">Román 1993</a>), DSM‐III (<a href="./references#CD010632-bbs2-0050" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington DC: American Psychiatric Association, 1987. ">APA 1987</a>), DSM‐IV (<a href="./references#CD010632-bbs2-0051" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV‐TR). 4th Edition. Washington DC: American Psychiatric Association, 1994. ">APA 1994</a>), ICD‐9 (<a href="./references#CD010632-bbs2-0081" title="World Health Organization. Statistical Classification of Diseases and Related Health Problems 9th Revision (ICD‐9). 6th Edition. Vol. Hospital edition, vols. 1, 2, 3, Los Angeles, CA: Practice Management Information Corporation (PMIC), 2006. ">ICD‐9 2006</a>) and ICD‐10 (<a href="./references#CD010632-bbs2-0080" title="World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10). available from apps.who.int/classifications/icd10/browse/2010/en.International (accessed 16th December 2012)2010. ">ICD‐10 2010</a>). </p> <p>The time interval over which progression from MCI to ADD or other forms of dementia occurs is important. We chose one year as the minimum period of delay in the verification of the diagnosis (i.e. the time between the assessment at which a diagnosis of MCI is made and the assessment at which the diagnosis of dementia is made). </p> </section> </section> <section id="CD010632-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <p>We used a variety of information sources, aiming to retrieve as many relevant studies as possible. The Trials Search Co‐ordinator of the CDCIG devised search strategies for electronic database searching. </p> <section id="CD010632-sec-0032"> <h4 class="title">Electronic searches</h4> <p>The most recent search for this review was performed in January 2013. We requested a search of the Cochrane Register of Diagnostic Test Accuracy Studies (managed by the Cochrane Renal Group). We also searched MEDLINE (OvidSP) (1950 to January 2013), MEDLINE (1950 to present), EMBASE (OvidSP) (1974 to week 2 2013), PsycINFO (OvidSP) (1806 to January week 2 2013), all databases in the Web of Science collection: Web of Science (1945 to present); BIOSIS Previews (1926 to present); Journal Citation Reports, and LILACS (Bireme). See <a href="./appendices#CD010632-sec-0056">Appendix 1</a> for details of the sources searched, the search strategies used, and the number of hits retrieved. We did not apply any language or date restrictions to the electronic searches; we did not use methodological filters, so as to maximise sensitivity (<a href="./references#CD010632-bbs2-0055" title="BeynonR , LeeflangMM , McDonaldS , EisingaA , MitchellRL , WhitingP , et al. Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE. Cochrane Database of Systematic Reviews2013, Issue 9. [DOI: 10.1002/14651858.MR000022.pub3] ">Beynon 2013</a>; <a href="./references#CD010632-bbs2-0128" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al: QUADAS‐2 Group. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>). </p> </section> <section id="CD010632-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all relevant studies for additional studies. We also conducted searches in the MEDION database (Meta‐analyses van Diagnostisch Onderzoek) at <a href="http://www.mediondatabase.nl/" target="_blank">www.mediondatabase.nl</a>, Database of Abstracts of Reviews of Effects (DARE) at <a href="http://www.crd.york.ac.uk/CRDWeb/" target="_blank">www.crd.york.ac.uk/CRDWeb/</a>, Health Technology Assessments Database (HTA Database) at <a href="http://www.crd.york.ac.uk/CRDWeb/" target="_blank">www.crd.york.ac.uk/CRDWeb/</a>, and Aggressive Research Intelligence Facility (ARIF) database at <a href="http://www.arif.bham.ac.uk/" target="_blank">www.arif.bham.ac.uk</a> for other related systematic diagnostic accuracy reviews. We searched for systematic reviews of diagnostic studies from the International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence‐based Laboratory Medicine database (C‐EBLM). We checked reference lists of any relevant systematic reviews for additional studies. </p> </section> </section> <section id="CD010632-sec-0034"> <h3 class="title" id="CD010632-sec-0034">Data collection and analysis</h3> <section id="CD010632-sec-0035"> <h4 class="title">Selection of studies</h4> <p>The CDCIG Trials Search Co‐ordinator (TSC), who is a researcher with experience of DTA systematic reviews, performed the first assessment of the search results in order to remove the obviously non‐relevant studies. Two review authors independently reviewed the remaining titles and abstracts for potentially eligible studies for full paper review. Two review authors then independently assessed full manuscripts against the inclusion criteria. Where necessary, a third review author resolved disagreements that the other two were not able to resolve through discussion. </p> <p>Where a study did not present all relevant data (for creating a 2 x 2 table) in the published manuscript, we contacted the authors directly to request further information. When the same dataset was presented in more than one paper, we planned to include the primary paper, which is the paper with the largest number of participants or with the most informative data. </p> <p>We detailed the number of studies selected at each point in a Study flow diagram (below).</p> </section> <section id="CD010632-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following data on study characteristics (if reported):</p> <p><i>Bibliographic details of primary paper:</i> </p> <p> <ul id="CD010632-list-0011"> <li> <p>Author, title of study, year and journal</p> </li> </ul> </p> <p><i>Basic clinical and demographic details:</i> </p> <p> <ul id="CD010632-list-0012"> <li> <p>Number of participants</p> </li> <li> <p>MCI clinical criteria</p> </li> <li> <p>Age</p> </li> <li> <p>Gender</p> </li> <li> <p>Referral centre(s)</p> </li> <li> <p>Participant recruitment</p> </li> <li> <p>Sampling procedures</p> </li> </ul> </p> <p><i>Details of the index test:</i> </p> <p> <ul id="CD010632-list-0013"> <li> <p>Method of the ¹⁸F‐FDG PET index test administration, including who administered the test </p> </li> <li> <p>Thresholds used to define positive and negative tests</p> </li> <li> <p>Other technical aspects as seem relevant to the review, e.g. brain areas</p> </li> </ul> </p> <p><i>Details of the reference standard:</i> </p> <p> <ul id="CD010632-list-0014"> <li> <p>Definition of ADD and other dementias used in reference standard</p> </li> <li> <p>Duration of follow‐up from time of index test used to define ADD and other dementias in reference standard: 1 to &lt; 2 years; 2 to &lt; 4 years; and &gt; 4 years; if participants have been followed for varied amounts of time we recorded a mean follow‐up period for each included study </p> </li> <li> <p>Prevalence or proportion of population developing ADD and other dementias, with severity, if described </p> </li> </ul> </p> <p>We created 2 x 2 tables (cross‐relating index test results of the reference standards) as shown in <a href="./appendices#CD010632-sec-0057">Appendix 2</a>. We also extracted data necessary for the assessment of quality, as defined below. Two blinded review authors (NS, CS) extracted data independently, resolving disagreements in data extraction by discussion, and involving a third review author (CH) as arbiter when necessary. </p> </section> <section id="CD010632-sec-0037"> <h4 class="title">Assessment of methodological quality</h4> <p>We assessed the methodological quality of each study using the QUADAS‐2 tool (<a href="./references#CD010632-bbs2-0128" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al: QUADAS‐2 Group. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>), as recommended by The Cochrane Collaboration. The tool is made up of four domains: i) Participant selection; ii) Index test; iii) Reference standard; iv) Participant flow. </p> <p>Two independent raters (NS, SM), blinded to each other’s scores, performed the QUADAS‐2 assessment, resolving disagreement by further review and discussion, with potential to involve a third review author (CH) as arbiter if necessary. We assessed each domain in terms of risk of bias, with the first three domains also considered in terms of applicability. The components of each of these domains and a rubric which details how judgements concerning risk of bias are made are detailed in <a href="./appendices#CD010632-sec-0058">Appendix 3</a> and <a href="./appendices#CD010632-sec-0059">Appendix 4</a>. Certain key areas important to quality assessment are participant selection, blinding and missing data. </p> <p>We did not use QUADAS‐2 data to form a summary quality score in order to ensure that the nature of the limitations of the studies were as transparent as possible. We produced a narrative summary describing numbers of studies that were found to have high/low/unclear risk of bias as well as concerns regarding applicability. </p> </section> <section id="CD010632-sec-0038"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We evaluated test accuracy according to target condition. There are no accepted thresholds to define ¹⁸F‐FDG PET positivity for Alzheimer's disease dementia and other forms of dementia, and so the estimates of diagnostic accuracy reported in primary studies were likely to be based on data‐driven threshold selection (<a href="./references#CD010632-bbs2-0088" title="LeeflangMMG , DeeksJJ , GatsonisC , BossuytPMM . Systematic reviews of diagnostic test accuracy. Annals of Internal Medicine2008; Vol. 149, issue 12:889. ">Leeflang 2008</a>). We conducted exploratory analyses by plotting estimates of sensitivity and specificity from each study in forest plots and in receiver operating characteristic (ROC) space. We meta‐analysed pairs of sensitivity and specificity using the hierarchical summary ROC (HSROC) model (<a href="./references#CD010632-bbs2-0119" title="RutterCM , GatsonisCA . A hierarchical regression approach to meta‐analysis of diagnostic test accuracy evaluations. Statistics in Medicine2001; Vol. 20, issue 19:2865‐84. [1097‐0258] ">Rutter 2001</a>) which allows for the possibility of variation in threshold between studies. Where inadequate studies were available to estimate all parameters, we assumed a symmetrical shape to the summary ROC curve. Estimates of summary sensitivities and specificities are not clinically interpretable when studies with mixed thresholds are included in the HSROC model, and so we derived estimates of sensitivity and likelihood ratios at fixed values (lower quartile, median and upper quartile) of specificity from the HSROC models. We performed the analyses using the SAS software (version 9.2; <a href="http://archie.cochrane.org/sections/documents/view?version=z1403181423040272986333131017796%26format=REVMAN#REF-SAS-Institute-2011" target="_blank">SAS Institute 2011</a>, Cary, NC). </p> </section> <section id="CD010632-sec-0039"> <h4 class="title">Investigations of heterogeneity</h4> <p>In preliminary analyses, we visually examined forest plots of sensitivity and specificity, and SROC plots to explore the effect of the sources of heterogeneity. We investigated the effect of i) interpretation of PET scan (a combination of visual inspection and quantitative rCGMr evaluation interpretation or visual‐only interpretation) and ii) prespecification of threshold on the diagnostic accuracy of the ¹⁸F‐FDG PET index test. However as there were insufficient studies we did not perform meta‐regression (by including each potential source of heterogeneity as a covariate in the HSROC model) as planned (<a href="#CD010632-sec-0063">Differences between protocol and review</a>). </p> </section> <section id="CD010632-sec-0040"> <h4 class="title">Sensitivity analyses</h4> <p>Due to the limited number of studies evaluating ¹⁸F‐FDG PET for all dementia, we performed sensitivity analyses only for studies of ADD. This is a departure from the protocol (<a href="./references#CD010632-bbs2-0130" title="VacanteM , SmailagicN , SachpekidisC , HydeC , MartinS , UkoumunneO . The accuracy of 18FDG‐PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD010632] ">Vacante 2013</a>) and is explained in the <a href="#CD010632-sec-0063">Differences between protocol and review</a> section. </p> </section> <section id="CD010632-sec-0041"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not investigate reporting bias because of current uncertainty about how it operates in test accuracy studies and the interpretation of existing analytical tools such as funnel plots. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010632-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010632-sec-0042"></div> <section id="CD010632-sec-0043"> <h3 class="title" id="CD010632-sec-0043">Results of the search</h3> <p>The total number of records identified by the searches for this review was 9676. After de‐duplication, the Trials Search Co‐ordinator and two paid assessors with experience of screening citations for biomarker diagnostic test accuracy studies screened the titles and abstracts. In total, they assessed 397 full papers and conference abstracts for eligibility (<a href="#CD010632-fig-0001">Figure 1</a>). We included 16 papers, and discarded 349 for the following reasons: i) not MCI participants at baseline; ii) not a longitudinal study; iii) index test not a ¹⁸F‐FDG PET. In addition, we excluded 32 papers due to insufficient data for creating 2 x 2 tables (<a href="./references#CD010632-sec-0066" title="">Characteristics of excluded studies</a>). We found no extra studies through reference checking. We obtained usable data for seven studies (<a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. ">Anchisi 2005</a>; <a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a>; <a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a>; <a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>; <a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>) through contacting the authors. </p> <div class="figure" id="CD010632-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010632-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p><b>Included Studies</b> </p> <p>The <a href="http://archie.cochrane.org/sections/documents/view?version=z1310081101152248131802582459257%26format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table lists the details of the 16 included studies covering 697 participants with MCI at baseline, of whom 595 had analysable data. Three studies (<a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>; <a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>) recruited participants from the same cohort (ADNI participants). The studies have been published over a 14‐year period (1999 to 2013). Most of them (13/16) were conducted in Europe (five in Italy, four in The Netherlands, two in Germany, one in Sweden and one in France), and three in the USA. Fourteen included studies used a version of the Petersen criteria for MCI. Thirteen studies applied NINCDS‐ADRDA criteria as a reference standard for ADD (<a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. ">Berent 1999</a> also used ICD‐10 while <a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a> and <a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. ">Nobili 2008</a> also used DSM‐IV; <a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>, <a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a> and <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a> did not specify the reference standard at follow‐up). </p> <p>Demographic and participant characteristics are summarised in <a href="#CD010632-tbl-0004">Table 3</a>. Study sizes were small and ranged from 19 to 94 participants. Five papers have a mean age of under 70 years (<a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. ">Arnáiz 2001</a>; <a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>; <a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. ">Mosconi 2004</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>; <a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>); <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a> did not report demographic data on the sample with ¹⁸F‐FDG PET scan. The youngest sample was aged 64.0 ± 9.0 (<a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>) and the oldest sample was aged 78.3 ± 7.5 (<a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>). Seven studies included more men than women in the samples included in the analysis (range from 33% to 75%); three studies did not reported gender for those samples (<a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>; <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>). APOE Ɛ4 gene carriers and sampling procedure were poorly reported. Participants were mainly recruited from university departments, clinics or research centres (seven studies) while three studies did not report their sources of recruitment (<a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. ">Chételat 2003</a>; <a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. ">Mosconi 2004</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>). Most of the studies did not clearly report whether participants were recruited from secondary or tertiary outpatient care settings. </p> <div class="table" id="CD010632-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Demographic and participant characteristics of participants included in analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N / n (included in analysis)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age converters (non‐converters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Gender</b> </p> <p><b> (M %) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MMSE score</b> </p> <p><b> converters (non‐converters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> APOE Ɛ4 carrier (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MCI diagnostic criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sampling</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sources of referral</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sources of recruitment</b> </p> <p><b> (setting)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. "><b>Anchisi 2005</b> </a> </p> <p><b>(Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67/48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.1 ± 73.9</p> <p>(65.0 ± 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (52.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6 ± 1.7</p> <p>(28.4 ± 1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0108" title="PattersonJC , LilienDL , TakalkarA , PinkstonJB . Early detection of brain pathology suggestive of early AD using objective evaluation of FDG‐PET scans. International Journal of Alzheimer's Disease2010; Vol. 2011:ii. 946590. [DOI: 10.4061/2011/946590] ">Patterson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> <p>(email from the author on 22nd October 2013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP surgeries</p> <p>(email from the author on 22nd October 2013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients from</p> <p>4 University Departments (Milan, Brescia, Cologne and Dresden)</p> <p>(email on 22nd October 2013)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. "><b>Arnáiz 2001</b> </a> </p> <p><b>(Sweden)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9 ± 8.3</p> <p>(60.1 ± 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (60.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 ± 1.8</p> <p>(27.2 ± 2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global Deterioration Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geriatric University clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. "><b>Berent 1999</b> </a> </p> <p><b>(USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 ± 5.5</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (65.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0 ± 1.9</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AAMI</p> <p>criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive disorders University clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chételat 2003</b> </p> <p><b> (France)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.0 ± 5.1</p> <p>(67.8 ± 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (45.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3 ± 1.0</p> <p>(27.8 ± 1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0110" title="PetersenRC , DoodyR , KurzA , MohsRC , MorrisJC , RabinsPV , et al. Current concepts in mild cognitive impairment. Archives of Neurology2001; Vol. 58, issue 12:1985‐92. ">Petersen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. "><b>Clerici 2009</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.2 ± 6.9</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2 ± 1.7</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0112" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004; Vol. 256, issue 3:183‐94. [1365‐2796] ">Petersen 2004</a> and CDR = 0.5 criteria </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP surgeries or specialists (85%) or self referral (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Centre for Research and Treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. "><b>Drzezga 2005</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.7 ± 4.7</p> <p>(67.6 ± 2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (46.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.9 ± 2.1</p> <p>(27.6 ± 1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (56.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> and CDR = 0.5 criteria </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP surgeries or</p> <p>specialists or other institutions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Research Unit</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. "><b>Fellgiebel 2007</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.5 ± 7.9</p> <p>(68.8 ± 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (56.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3 ± 1.5</p> <p>(27.3 ± 1.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University memory clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. "><b>Galluzzi 2010</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.0 ± 7.1</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (41.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.1 ± 1.8</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (38.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient memory clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. "><b>Herholz 2011</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0 ± 7.6</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (70.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2671 ± 1.6</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0114" title="PetersenRC , AisenPS , BeckettLA , DonohueMC , GamstAC , HarveyDJ , et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology2010;74(3):201‐9. ">Petersen 2010</a> &amp; </p> <p>CDR = 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre (not specified)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. "><b>Landau 2010</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.3 ± 7.5</p> <p>(78.0 ± 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (65.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4 ± 1.7</p> <p>(27.3 ± 1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (29.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Petersen 2010 &amp;</p> <p>CDR=0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter (not specified)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. "><b>Mosconi 2004</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0 ± 4.0</p> <p>(63.0 ± 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (45.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.9 ± 1.7</p> <p>(28.1 ± 1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (43.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0114" title="PetersenRC , AisenPS , BeckettLA , DonohueMC , GamstAC , HarveyDJ , et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology2010;74(3):201‐9. ">Petersen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. "><b>Nobili 2008</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3 ± 4.8</p> <p>(74.6 ± 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (39.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0 ± 4.0</p> <p>(63.0 ± 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on all MCI included in analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0112" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004; Vol. 256, issue 3:183‐94. [1365‐2796] ">Petersen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. "><b>Ossenkoppele 2012a</b> </a> </p> <p><b> (Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.0 ± 7.0</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (75%)</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0 ± 7.6</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (66.7)</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. "><b>Ossenkoppele 2012b</b> </a> </p> <p><b> (Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.0 ± 9.0</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (30.4)</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0 ± 7.6</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0110" title="PetersenRC , DoodyR , KurzA , MohsRC , MorrisJC , RabinsPV , et al. Current concepts in mild cognitive impairment. Archives of Neurology2001; Vol. 58, issue 12:1985‐92. ">Petersen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient University memory clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a> </p> <p><b> (USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/18 Reader 1</p> <p>19/19 Reader 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 80.0 (range 54 ‐ 83)</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geriatric, Research, Education and Medical Centre</p> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. "><b>Schmand 2012</b> </a> </p> <p><b> (Netherlands)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89/89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0114" title="PetersenRC , AisenPS , BeckettLA , DonohueMC , GamstAC , HarveyDJ , et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology2010;74(3):201‐9. ">Petersen 2010</a> &amp; </p> <p>CDR = 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre (not specified)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADNI: Alzheimer's Disease neuroimaging initiative</p> </div> </div> <p><a href="#CD010632-tbl-0005">Table 4</a> summarises the data regarding the threshold used, image scaling, brain region as potential Alzheimer's disease areas, ¹⁸F‐FDG dose and the time between ¹⁸F‐FDG injection and performing a PET scan, the number of ¹⁸F‐FDG‐positive participants at baseline and the number of converters during the follow‐up period. </p> <div class="table" id="CD010632-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Index test and numbers of converters to Alzheimer’s disease dementia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Threshold</b> </p> <p><b> (prespecified</b> </p> <p><b> Yes/No)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Image scaling</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Discriminating brain area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Image analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time between FDG injection and PET acquisition (min)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>¹⁸F‐FDG dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of ¹⁸F‐FDG positive</b> </p> <p><b> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of converters (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of follow‐up</b> </p> <p><b> Mean (months) / Maximum (years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. "><b>Anchisi 2005</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of temporo‐parietal and posterior cingulate of 1.138</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regional sensorimotor</p> <p>FDG uptake ratio (p 1730)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bilateral parietal and posterior cingulate cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (40)</p> <p>(calculated in RevMan5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 12 months</p> <p>Range: 12 ‐ 27 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. "><b>Arnáiz 2001</b> </a> </p> <p><b>(Sweden)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of left temporo‐parietal region 13 mm above the basal ganglia</p> <p>(Model I)</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensorimotor</p> <p>area of the cortex 26 mm above the level of the basal ganglia (p 852)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporo‐parietal cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> <p>(<a href="./references#CD010632-bbs2-0077" title="HerholzK , NordbergA , SalmonE , PeraniD , KesslerJ , MielkeR , et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders1999;10(6):494–504. ">Herholz 1999</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (40)</p> <p>(calculated in RevMan5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. "><b>Berent 1999</b> </a> </p> <p><b> (USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of</p> <p>diagnostic index based on Z‐scores of the parietal cortex</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thalamus (p 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, temporal, parietal and occipital regions normalised to the thalamus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3D‐SSP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. "><b>Chételat 2003</b> </a> </p> <p><b> (France)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc at Z‐score of &gt; 3.09</p> <p>Thresholding was set at 80% of whole brain mean of control subjects</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FDG uptake normalised by and adjusted to the person’s global uptake (p 1375)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right temporo‐parietal and posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (41)</p> <p>right temporo‐parietal region</p> <p>8 (47.0) posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. "><b>Clerici 2009</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc</p> <p>lower than the control group corresponding to a P value &lt; 0.01 level)</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global counts were normalised by proportional scaling to remove confounding effects due to global changes </p> <p>(<a href="./references#CD010632-bbs2-0066" title="DelSoleA , ClericiF , ChitiA , LecchiM , MarianiC , MagioreL , et al. Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG‐PET study. European Journal of Nuclear Medicine and Molecular Imaging2008;35(7):1357‐66. ">Del Sole 2008</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Posterior gyrus cingulate and bilateral inferior frontal cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM(t)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185‐370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (88.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 years aMCI group.</p> <p>3 years snaMCI group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. "><b>Drzezga 2005</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc at</p> <p>Z‐score of &gt; 1.64 (1‐tail) corresponding to a P value of 0.05 (1‐tail)</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orbitofrontal, prefrontal, premotor, central, parietal superior and inferior, occipital, temporal anterior, temporal posterior and posterior cingulate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3D‐SSP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 ± 2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. "><b>Fellgiebel 2007</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc at</p> <p>significantly decreased Z‐score &gt; 2 in more than 50 adjacent pixels</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensorimotor</p> <p>area of the cortex (transaxial images parallel to the intercomissural line)</p> <p>(<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parietal mesial or posterior cingulate and temporal regions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> <p>(<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 MBq (<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 ± 9.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. "><b>Galluzzi 2010</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of</p> <p>t sum &gt; 11.090 (email from the author)</p> <p>(<a href="./references#CD010632-bbs2-0078" title="HerholzK , SalmonE , PeraniD , BaronJ , HolthoffV , FrölichL , et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage2002; Vol. 17, issue 1:302‐16. [1053‐8119] ">Herholz 2002</a>) </p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporo‐parietal, hippocampus and posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6.6 ± 9.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. "><b>Herholz 2011</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of</p> <p>t sum &gt; 11.090</p> <p>(<a href="./references#CD010632-bbs2-0078" title="HerholzK , SalmonE , PeraniD , BaronJ , HolthoffV , FrölichL , et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage2002; Vol. 17, issue 1:302‐16. [1053‐8119] ">Herholz 2002</a>) </p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporal and parietal lobes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PALZ (PMOD software)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 ‐ 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. "><b>Landau 2010</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of 1.21</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellar vermis and pons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROI interest were study‐independent, frequently associated with decline in AD and MCI. No further details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 ‐ 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 ± 0.4 years Range: 2 ‐ 3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. "><b>Mosconi 2004</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCMRglc significantly reduced in certain cerebral areas with emphasis on the inferior parietal lobule (IPL). </p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Precuneus, anterior and posterior cingulate, inferior parietal lobe, superior, middle and inferior frontal gyrus, on both hemispheres </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 ± 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 ‐ 370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (10.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 ± 0.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. "><b>Nobili 2008</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection</p> <p>rCGMglc threshold not reported</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 VROI in each hemisphere</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computerized Brain Atlas (CBA;</p> <p>Applied Medical Imaging©, Uppsala, Sweden)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 ± 10.9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. "><b>Ossenkoppele 2012a</b> </a> </p> <p><b>(Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection and SUVr of ROIs (threshold not reported) (No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellar grey matter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, parietal and latero‐temporal and medial temporal lobes and posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PMOD Alzheimer discrimination tool (PALZ)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ‐ 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 ± 17 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>Range: 2 ‐ 4 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. "><b>Ossenkoppele 2012b</b> </a> </p> <p><b>(Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection and SUVr of ROIs (threshold not reported) (No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellar grey matter (p 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, parietal, occipital, and latero‐temporal and medial temporal lobes and posterior cingulate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PMOD Alzheimer discrimination tool (PALZ)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a> </p> <p><b> (USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection</p> <p>Hypomethabolism if &lt; 50% of the cubes had the label MCI or normal</p> <p>(Only SVM analysis used thresholds)</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PET scans were adjusted to a whole‐brain mean activity and stereotactically normalised by using Neurostat (p 328) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, parietal, occipital, and latero‐temporal and medial temporal lobes and posterior cingulate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SVM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mCi/70 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reader 1:</p> <p>6(32)</p> <p>Reader 2:</p> <p>10 (53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (44)</p> <p>9 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. "><b>Schmand 2012</b> </a> </p> <p><b> (Netherlands)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGM value of &lt; 1.20</p> <p>(Email from the author)</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left angular gyrus, bilateral posterior cingulate gyrus and left middle/inferior temporal gyrus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 ± 0.9</p> <p>Range: 0.5 ‐ 4.6 years</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADNI: Alzheimer's Disease neuroimaging initiative<br/> RevMan5: Review Manager 5 software<br/> SUVr: standardised uptake value ratio<br/> VROI: volumetric region of interest </p> </div> </div> <p>All included studies applied qualitative/visual evaluations of the PET scans. In particular, 12 of the 16 studies performed PET analysis based on the combination of visual analysis (qualitative) and rCGMr estimations (quantitative), while the remaining four studies referred only to visual PET inspections (qualitative‐only analysis). A range of different thresholds were applied (different rCGMr values, various brain regions studied as potential Alzheimer's disease areas, as well as different scaling). The threshold was prespecified in only six studies (<a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a>; <a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. ">Drzezga 2005</a>; <a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>; <a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a>; <a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>). ¹⁸F‐FDG positivity ranged from 10.5% (<a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. ">Mosconi 2004</a>) to 74% (<a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a>) (<a href="#CD010632-tbl-0006">Table 5</a>). Conversion to ADD ranged from 22% (<a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. ">Mosconi 2004</a>) to 50% (<a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. ">Berent 1999</a>; <a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>). </p> <div class="table" id="CD010632-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of test accuracy at study level for conversion to Alzheimer’s disease dementia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Studies included in meta‐analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participants (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Specificity (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> % of MCI with ¹⁸F‐FDG PET positivity </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. "><b>Anchisi 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. "><b>Arnáiz 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. "><b>Berent 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. "><b>Chételat 2003</b> </a> </p> <p><b>(temporo‐parietal brain region)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. "><b>Clerici 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. "><b>Drzezga 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. "><b>Fellgiebel 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. "><b>Galluzzi 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. "><b>Herholz 2011</b> </a><b> (ADNI study)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. "><b>Mosconi 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. "><b>Nobili 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. "><b>Ossenkoppele 2012a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. "><b>Ossenkoppele 2012b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a><b>(Reader 1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> Studies included only in descriptive analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. "><b>Chételat 2003</b> </a> </p> <p><b>(posterior cingulate brain region)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. "><b>Landau 2010</b> </a><b> (ADNI study)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a><b> (Reader 2)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. "><b>Schmand 2012</b> </a><b> (ADNI study)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADNI: Alzheimer's Disease neuroimaging initiative</p> </div> </div> <p>Duration of follow‐up was reported as the mean and standard deviation (SD), or the median, or a range of values. </p> </section> <section id="CD010632-sec-0044"> <h3 class="title">Methodological quality of included studies</h3> <p>We assessed methodological quality using the QUADAS‐2 tool (<a href="./references#CD010632-bbs2-0128" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al: QUADAS‐2 Group. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>). We present the review authors’ judgements about each methodological quality item for each included study in the <a href="./references#CD010632-sec-0065" title="">Characteristics of included studies</a> table and <a href="#CD010632-fig-0002">Figure 2</a>. The overall methodological quality of included study cohorts is summarised in <a href="#CD010632-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010632-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD010632-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <div class="figure" id="CD010632-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD010632-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> </div> <p>In the participant selection domain, we considered five studies (<a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. ">Berent 1999</a>; Chételat 2003; <a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>; <a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>; <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a>) to be at high risk of bias because the participants were not consecutively or randomly enrolled. We had excluded studies with a case‐control design because we only considered data on performance of the index test to discriminate between participants with MCI who convert to dementia and those who remained stable. We considered four studies (<a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. ">Arnáiz 2001</a>; <a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a>; <a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. ">Nobili 2008</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>) to be at unclear risk of bias due to poor reporting on sampling procedure and exclusion criteria. We considered the remaining seven (44%) studies to be at low risk of bias. </p> <p>In the index test domain, we considered nine (56%) studies (<a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. ">Anchisi 2005</a>; <a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. ">Arnáiz 2001</a>; <a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. ">Berent 1999</a>; <a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. ">Chételat 2003</a>; <a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>; <a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. ">Nobili 2008</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>; <a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>; <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a>) to be at high risk of bias because the threshold used was not prespecified and the optimal cut‐off level was determined from ROC analyses; therefore, the accuracy of the ¹⁸F‐FDG biomarker reported in these studies appeared to be an overestimate. We considered one study (<a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. ">Mosconi 2004</a>) to be at unclear risk of bias due to poor reporting. We considered the remaining six (38%) studies to be at low risk of bias. </p> <p>In the reference standard domain, we considered 11 studies (69%) to be at unclear risk of bias, mainly because they did not report whether clinicians conducting follow‐up were aware of the initial ¹⁸F‐FDG biomarker analysis results. One of the 11 studies (<a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>) did not clearly report the reference standards used for diagnosing ADD. We considered two studies (<a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>; <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a>) to be at high risk of bias because they failed to provide information on either item in this domain. We were not able to obtain the information about how the reference standard was obtained and by whom, due to poor reporting. We considered the remaining three studies (<a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. ">Berent 1999</a>; <a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. ">Chételat 2003</a>; <a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. ">Drzezga 2005</a>) to be at low risk of bias. </p> <p>In the flow and timing domain, we judged 10 studies (62%) to be at low risk of bias because all participants were accounted for in the analysis or the reasons for missing data were given, and/or the time interval between index test and reference standard was appropriate (duration of follow‐up longer than one year). We considered three studies (19%) to be at high risk of bias, either because a large number of participants were excluded from the analyses (<a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. ">Anchisi 2005</a>; <a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>) or because the interval between index test and reference standard was shorter than one year for some participants (<a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. ">Nobili 2008</a>). We considered the remaining three studies (<a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a><a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>; <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a>) to be at unclear risk of bias due to poor reporting. </p> <p>For assessment of applicability, we had no concern that the included participants and setting, the conduct and interpretation of the index test, and the target condition (as defined by the reference standard) in each of the included studies did not meet the review question. It should be noted that the lack of concern about applicability of the three domains mentioned above was based on the inclusion criteria set for the review. Considering the level of heterogeneity with respect to the index test (<a href="#CD010632-tbl-0005">Table 4</a>), it appears that the judgement about applicability may be optimistic. </p> </section> <section id="CD010632-sec-0045"> <h3 class="title" id="CD010632-sec-0045">Findings</h3> <p>The key characteristics of each study are summarised in <a href="#CD010632-tbl-0004">Table 3</a> and <a href="#CD010632-tbl-0005">Table 4</a>. The summary of main results for 16 included studies is presented in the <a href="./full#CD010632-tbl-0001">summary of findings Table</a>. </p> <p><b>¹⁸<i>F‐FDG PET for Alzheimer's disease dementia</i> </b> </p> <p>We identified three studies that recruited participants from the same Alzheimer’s disease Neuroimaging Initiative (ADNI) cohort (<a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>; <a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>). The largest ADNI study (<a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>) was included in the analysis. </p> <p>The <a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. ">Chételat 2003</a> study assessed two different discriminating brain regions (temporo‐parietal and posterior cingulate). We included data for the temporo‐parietal region, since it represents a typical and 'wider' brain area that is potentially involved in conversion to ADD. </p> <p>In <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a> the PET scan was interpreted by two raters. As already mentioned, visual/qualitative reading of the ¹⁸F‐FDG PET scan is accepted as the general standard in nuclear medicine (similar to other imaging modalities). It is, therefore, heavily dependent on the physician’s prior experience and training. The quantitative assessment plays a rather complementary role in PET evaluations. The physician usually decides based on his or her own visual‐qualitative assessment. We included data from Reader 1 because it is very likely that Reader 1 is more experienced in interpreting brain PET scans. This rater provided more accurate estimates of the diagnostic accuracy of Alzheimer's disease type imaging comparing to diagnosis on follow‐up. </p> <p>Individual study estimates of sensitivity and specificity are shown in <a href="#CD010632-fig-0004">Figure 4</a> for each of the 14 studies (150 cases and 271 non‐cases) that evaluated ADD. The sensitivity values ranged from 25% to 100% while the specificity values ranged from 29% to 100%. The criteria for ¹⁸F‐FDG PET positivity varied between studies. Ten studies performed PET analysis based on the combination of visual analysis (qualitative) and rCGMr estimations (quantitative), and four studies only referred to visual PET inspections (qualitative‐only analysis). A range of different thresholds were used. The different brain regions were studied as potential Alzheimer's disease areas as well as different scaling. </p> <div class="figure" id="CD010632-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study). </p> </div> </div> </div> <p>The summary ROC curve presenting the accuracy of ¹⁸F‐FDG PET across the 14 studies is shown in <a href="#CD010632-fig-0005">Figure 5</a>. Because of the variation in thresholds and measurement of ¹⁸F‐FDG uptake in brain regions, we did not estimate a summary sensitivity and specificity. However, we derived estimates of sensitivity and likelihood ratios at fixed values of specificity from the HSROC model we fitted to produce the summary ROC curve. At the median specificity of 82%, the estimated sensitivity was 76% (95% confidence interval (CI): 53.80 to 89.70), the positive likelihood ratio was 4.03 (95% CI: 2.97 to 5.47), and the negative likelihood ratio was 0.34 (95% CI: 0.15 to 0.75). </p> <div class="figure" id="CD010632-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study). </p> </div> </div> </div> <p>In order to demonstrate whether the choice of ADNI study or discriminating brain region or reader assessment made any differences to the pooled estimate, we performed five additional analyses. At the median specificity of 82%, the estimated sensitivity ranged from 74% to 77%. There was no impact on our findings. </p> <p><b>¹⁸<i>F‐FDG PET for all types of dementia (combined AD and non‐AD dementia)</i> </b> </p> <p>Five studies (64 cases and 42 non‐cases) evaluated the accuracy of ¹⁸F‐FDG PET for all dementia (<a href="#CD010632-fig-0006">Figure 6</a>) in addition to evaluating ADD. The sensitivity values ranged from 46% to 95%, while the specificity values ranged from 29% to 100%. Two studies used a semi‐quantitative threshold while the other three used visual inspection to determine test positivity. Meta‐analysis was not performed because the studies were too few and their sample sizes were too small. <a href="#CD010632-fig-0007">Figure 7</a> shows study specific estimates of sensitivity and specificity in ROC space together with their 95% confidence intervals. </p> <div class="figure" id="CD010632-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010)." data-id="CD010632-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010). </p> </div> </div> </div> <div class="figure" id="CD010632-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010)." data-id="CD010632-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010). </p> </div> </div> </div> <p>The estimate of sensitivity and specificity for the <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a> study was 46% and 80% for Reader 1, and 64% and 0% for the Reader 2. </p> <p><i><b>Investigation of heterogeneity</b> </i> </p> <p>We visually inspected the summary of ROC space (see Figure 5). The results of the included studies show a great deal of heterogeneity. The values for both sensitivity and specificity were mainly over 80% in a number of studies (<a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. ">Anchisi 2005</a>; <a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. ">Chételat 2003</a>; <a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. ">Drzezga 2005</a>; <a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>; <a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>; <a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>). In the remaining studies those values were less than 80% or a sensitivity value higher than 80% was accompanied by a very low specificity value and vice versa (<a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a>; <a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a>; <a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. ">Mosconi 2004</a>). </p> <p><b>Interpretation of PET scan</b> </p> <p>There was little evidence that the HSROC model which allowed the shape, accuracy and threshold parameters to differ between those studies using a combination of visual inspection and quantitative rCGMr evaluation interpretation and those using visual‐only interpretation provided an improvement in fit over the basic model where a single HSROC curve (Chi² = 1.7; df = 3; P = 0.64). </p> <p><b>Prespecifying threshold regarding rCGM</b> </p> <p>This investigation relates to the 10 studies in which semi‐quantitative estimation was used. Meta‐regression revealed little evidence of an improvement in fit between the basic model and the model that allowed the parameters to differ between those studies that did and did not specify a threshold (Chi² = 93.5 ‐ 88.3 = 5.2; df = 3; P = 0.16). </p> <p>The remaining planned investigations (for instance, the effect of the spectrum of participants, referral centres, ¹⁸F‐FDG uptake reduction brain regions, inadequate blinding or loss to follow‐up) were not possible due to the limited number of studies available for each analysis. We conducted sensitivity analyses for type of clinical diagnosis for MCI and for type of reference standard. </p> <p><i><b>Sensitivity analyses</b> </i> </p> <p>Of the 14 studies that evaluated ¹⁸F‐FDG PET for ADD, 12 used Petersen criteria for diagnosing MCI. To explore the impact of type of diagnostic criteria on the summary estimates, we excluded two studies (<a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. ">Arnáiz 2001</a>; <a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. ">Berent 1999</a>) that used the Global Deterioration Scale and AAMI respectively as the diagnostic criteria. There was no impact on our findings. </p> <p>Eleven studies used NINCDS‐ADRDA as the reference standard. To explore the impact of the type of reference standard on the summary estimates, we excluded one study (<a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>) that used CDR = 1, one study (<a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>) that used a non‐specified clinical dementia rating and the Alzheimer's Disease Assessment Scale (ADAS‐cog), and one study (<a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a>) where the reference standard used was not reported. There was no impact on our findings. </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010632-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010632-sec-0046"></div> <section id="CD010632-sec-0047"> <h3 class="title" id="CD010632-sec-0047">Summary of main results</h3> <p>For this review we identified 16 studies assessing the diagnostic accuracy of ¹⁸F‐FDG PET for conversion from mild cognitive impairment (MCI) to Alzheimer's disease dementia or to other forms of dementia. The key results are presented in <a href="./full#CD010632-tbl-0001">summary of findings Table</a>. Due to variation in thresholds and measurement of ¹⁸F‐FDG uptake in brain regions, we estimated a summary ROC curve for studies that evaluated conversion from MCI to Alzheimer's disease dementia. We did not estimate a summary sensitivity and specificity on the curve because with mixed thresholds a summary point lacks a clinically meaningful interpretation. At the median specificity of 82%, the estimated sensitivity of ¹⁸F‐FDG PET for conversion to Alzheimer's disease dementia derived from the summary ROC curve was 76% (95% confidence interval (CI): 53.80 to 89.70). </p> <p>We did not pool data for the five studies that evaluated conversion from MCI to all types of dementia. The sensitivities were between 46% and 95%, and specificities were between 29% and 100%. </p> <p>¹⁸<b>F‐FDG PET for Alzheimer’s disease dementia</b> </p> <p>We identified three Alzheimer's Disease Neuroimaging Initiative (ADNI) studies (<a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>; <a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>). ADNI is a multicentre project with approximately 50 medical centres and university sites across the United States and Canada; it has the primary goal of evaluating magnetic resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF), and clinical measures acquired serially over two to three years. The aims of the three studies differed. <a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a> demonstrated the validity of ¹⁸F‐FDG PET scores as an imaging biomarker for clinical trials to prevent dementia in people with MCI. Longitudinal ADNI data showed that PET scores provide much higher test–retest reliability than the Alzheimer's Disease Assessment Scale (ADAS‐cog), which is the most frequent outcome measure used in dementia trials. They argue that a PET scan evaluation may also provide a useful measure of disease progression, as the power for one‐year studies in people with MCI is similar to what they provide for two‐year studies based on progression of ADAS‐cog scores. <a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a> evaluated the prognostic ability of genetic, CSF, neuroimaging, and cognitive measurements obtained in the same participants. The authors concluded that baseline ¹⁸F‐FDG PET and episodic memory predict conversion to ADD, whereas P‐tau<sub>181p</sub>/Aβ<sub>1‐42</sub> and, marginally, ¹⁸F‐FDG PET predict longitudinal cognitive decline. <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a> examined the value of neuropsychological assessment, structural MRI, CSF biomarkers, and ¹⁸F‐FDG PET scanning with respect to prediction of conversion from MCI to ADD. The authors’ practical conclusions were that these markers are not very useful, either with respect to the diagnosis of ADD beyond the age of 75, or with respect to the prediction of conversion to ADD within a few years. In younger people, all four techniques were equally informative, except for ¹⁸F‐FDG PET, which lost its predictive potential. We created 2 x 2 tables cross‐relating index test results of the reference standard for each ADNI study. The sensitivity and specificity values vary in those studies. All three studies used a combination of visual inspection and quantitative (rCGMr) evaluation of the PET scan, but the threshold, brain regions, image scaling and analysis used differed between them. The number of participants with positive ¹⁸F‐FDG test at baseline also varied (<a href="#CD010632-tbl-0006">Table 5</a>). Although the samples were recruited from the same ADNI cohort, it appears that test accuracy varies due to characteristics of the participants and index test domains. We have included the largest ADNI study (<a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. ">Herholz 2011</a>) in the analysis. </p> <p>The <a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. ">Chételat 2003</a> study assessed both the temporo‐parietal and posterior cingulate regions. We included data for the temporo‐parietal region. Although the posterior cingulate cortex represents the brain area in which hypometabolism occurs in the earliest disease stage (<a href="./references#CD010632-bbs2-0089" title="LucignaniG , FrostJF . Neurochemical imaging with emission tomography: Clinical applications. link.springer.com/chapter/10.1007/3‐540‐30005‐8_2#page‐1Diagnostic nuclear medicine (accessed January 12 2015) 2006. ">Lucignani 2006</a>), the bilateral temporo‐parietal hypometabolism is the standard ¹⁸F‐FDG PET finding, which is also highly correlated with the pathologic diagnosis of ADD (<a href="./references#CD010632-bbs2-0079" title="HoffmanJM , Welsh‐BohmerKA , HansonM , CrainB , HuletteC , EarlN , et al. FDG PET imaging in patients with pathologically verified dementia. Journal of Nuclear Medicine2000;41(11):1920‐8. ">Hoffman 2000</a>). Moreover, it has been suggested that hypometabolism or hypoperfusion or both in the inferior parietal lobules are the most reliable functional indicators of progression from amnestic MCI to ADD, while changes in the posterior cingulate cortex are most likely non‐specific (<a href="./references#CD010632-bbs2-0120" title="SchroeterML , SteinT , MaslowskiN , NeumannJ . Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta‐analysis involving 1351 patients. NeuroImage2009; Vol. 47, issue 4:1196‐206. [1053‐8119] ">Schroeter 2009</a>). </p> <p>In addition<i>,</i> in the <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a> study two independent blinded raters with experience in PET evaluated each image as normal or as having an Alzheimer's disease or fronto‐temporal dementia (FTD) pattern. The physicians usually based the decision on their own visual‐qualitative assessment. We therefore included data from Reader 1 because it is very likely that Reader 1 was more experienced in interpreting brain PET scans. </p> <p>In order to explore whether the choice of ADNI study or discriminating brain region or reader assessment make any differences to the pooled estimate, we performed five additional analyses. The estimated sensitivity values at the median specificity of 82% were similar to the sensitivity value in our analysis (ranging from 74% to 77%). </p> <p>In all studies ¹⁸F‐FDG PET data evaluation involved qualitative (visual) assessment of the PET scans, and in some of them this visual analysis was supported by the addition of semi‐quantitative data (mainly through rCGMr estimations), derived from quantification of brain PET images. In particular, 12 of the 16 studies applied a combination of qualitative and quantitative assessment, while the remaining four were based only on visual data analysis. This discrepancy introduces a degree of heterogeneity into our analysis. Moreover, and as already mentioned, the application of different thresholds in PET studies for the specific brain area examined and the glucose metabolism ratio applied as a threshold for discriminating a pathological from a normal scan, introduces a further degree of heterogeneity. The use of quantification methods is not the norm in routine clinical practice. However, their deployment has become more popular in recent years with the development of new software, which renders quantification simpler. In general terms, there are two categories of quantification methods: the ‘traditional’ region of interest (ROI) based method, which are manually operated, and the newer voxel‐based, which provide relatively automated results. The ROI‐based method has the disadvantage of being operator‐dependent and therefore time‐intensive. This approach requires a high level of neuro‐anatomical knowledge by the physician, which is particularly demanding in the case of ADD, in which several specific brain areas need to be assessed. The advent of newer voxel‐by‐voxel‐based techniques ((like SPM (statistical parametric mapping), 3D‐SSP (3D stereotactic surface projection) and PMOD software package, which were used in the majority of the studies involved in this meta‐analysis)) that permit normalisation of brain images into a stereotactic space and are less biased and provide higher spatial resolution than the ‘classical’ ROI‐based semi‐quantitative methods, increase the physician’s diagnostic accuracy in the interpretation of a brain PET scan, leading to more reliable results (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405211158586018490419480445199%26format=REVMAN#REF-Lucignani-2006" target="_blank">Lucignani 2006</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405211158586018490419480445199%26format=REVMAN#REF-Patterson-2010" target="_blank">Patterson 2010</a>; <a href="./references#CD010632-bbs2-0123" title="SilvermanDHS . Clinical interpretation of brain PET scans: performing visual assessments, providing quantifying data, and generating integrated reports. In: SilvermanDHS editor(s). PET in the Evaluation of Alzheimer’s Disease and Related Disorders. New York: Springer, 2009:33‐49. ">Silverman 2009</a>). In this context, the application of different quantification strategies is another factor that could introduce heterogeneity between studies in this review. </p> <p>Duration of follow‐up is also important in predicting conversion to ADD. The variability in the duration of follow‐up was considerable in the included studies (<a href="#CD010632-tbl-0005">Table 4</a>). The normal conversion rate of MCI to ADD is between 8% and 16% per year (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405211107149708053157138814538%26format=REVMAN#REF-Mitchell-2009" target="_blank">Mitchell 2009</a>), but the conversion rates in our review ranged from 22% to 50%. There was a positive correlation between follow‐up time and percentage of conversion. For example, in <a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. ">Berent 1999</a>, <a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a> and <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>, the conversion rate from MCI was 50%, with the duration of follow‐up ranging from two to three years. On the other hand, the lowest conversion rates of 22% and 25% were found in the studies (<a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. ">Mosconi 2004</a>; <a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. ">Fellgiebel 2007</a>) with the shortest duration of follow‐up (mean 12 ± 0.6 and 19.6 ± 9.0 months respectively). Conversion rates from MCI could have influenced the test results. However, we were not able to formally investigate the effect of duration of follow‐up on the accuracy of the ¹⁸F‐FDG PET, due to a high level of heterogeneity and the small number of included studies. </p> <p>We used the QUADAS‐2 tool to assess methodological quality. We identified methodological issues in all the QUADAS‐2 domains. Assessment of quality is dependent on adequate reporting, and QUADAS scoring was challenging because of insufficient detail. Poor reporting about sampling procedures led mainly to an unclear risk of bias or contributed to a high risk of bias in the participant selection domain. Although the reference standard was regarded as adequate to correctly classify the target condition, poor reporting on blinding of dementia assessors led to an unclear risk of bias in the reference domain in the majority of included studies. </p> <p><b>¹⁸F‐FDG PET for other forms of dementia</b> </p> <p>We were not able to evaluate the accuracy of the index test for conversion from MCI to non‐Alzheimer’s disease dementia, due to insufficient data. Only five included studies (<a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a>; <a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405080903349424399118555914889%26format=REVMAN#STD-Ossenkoppele-2012a" target="_blank">Ossenkoppele 2012a</a>; <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a>) reported a small number of converters to non‐Alzheimer’s dementia. <a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a> and <a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a> reported six converters respectively (two FTD; four Lewy body dementia (LBD); six non‐Alzheimer's Disease non‐specified). The remaining three studies reported only one converter each (three FTD). </p> <p>As a result of the information available from these five studies, we considered the new target condition (<a href="#CD010632-fig-0006">Figure 6</a> and <a href="#CD010632-fig-0007">Figure 7</a>). We did not perform meta‐analysis because the studies were few and small, and there was considerable heterogeneity. Our review therefore suggests that there is inadequate evidence available at present to address the accuracy of the ¹⁸F‐FDG PET scan to identify those people with MCI who will convert to all types of dementia (combined Alzheimer's and non‐Alzheimer's disease dementia). </p> </section> <section id="CD010632-sec-0048"> <h3 class="title" id="CD010632-sec-0048">Strengths and weaknesses of the review</h3> <p>One strength of our review is that the included studies represent probably the majority of studies about this question. We conducted an extensive electronic search strategy, and where a study did not present all relevant data we contacted the study authors and obtained usable data for seven studies (<a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. ">Anchisi 2005</a>; <a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. ">Clerici 2009</a>; <a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. ">Galluzzi 2010</a>; <a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. ">Landau 2010</a>; <a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. ">Ossenkoppele 2012a</a>; <a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. ">Ossenkoppele 2012b</a>; <a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. ">Schmand 2012</a>). </p> <p>Our review has some limitations. First, the clinical diagnosis of ADD or other forms of dementia is imperfect, so that the findings from studies with post‐mortem confirmation of the diagnosis are more convincing than those from studies with a clinical diagnosis in the evaluation of the accuracy of PET imaging for the early detection of the dementia process in people with MCI. </p> <p>The findings are based on studies with poor reporting and the majority of included studies were at an unclear risk of bias, mainly for the reference standard and for the participant selection domains. Although there was relative homogeneity in terms of scan acquisition protocol, the process followed and the fundamental evaluation approach that people demonstrating particular brain regions with reduced ¹⁸F‐FDG uptake represent potential MCI converters to ADD, according to the assessment of Index test domain more than 50% of studies were of poor methodological quality due to lack of a prespecified threshold. Index tests that require subjective interpretation (such as ¹⁸F‐FDG PET) are at high risk of bias for the index test domain compared to more objective tests with widely‐accepted thresholds. The <a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. ">Pardo 2010</a> study illustrates poor agreement between both experienced raters for the correlation between diagnosis at three‐year follow‐up and baseline ¹⁸F‐FDG PET scans classified as PET pattern (normal, ADD, and FTD). </p> <p>Due to the limited number of included studies and the meta‐analytic techniques, we were unable to formally assess the sources of heterogeneity, or to disentangle the reasons for the test accuracy results varying between studies, so even those factors that we have been able to test cannot be excluded as reasons for the heterogeneity. </p> </section> <section id="CD010632-sec-0049"> <h3 class="title" id="CD010632-sec-0049">Applicability of findings to the review question</h3> <p>We had no concerns that the included participants and setting, the conduct and interpretation of the index test, and the target condition (as defined by the reference standard) in each of the included studies did not address the review question<i>: Could</i> ¹⁸<i>F‐FDG PET scan predict whether people with MCI would convert clinically to dementia?</i> However, due to limited number of included studies and levels of heterogeneity in the three domains mentioned above, it was difficult to determine to what extent the findings from this meta‐analysis can be applied to clinical practice. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010632-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010632-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD010632-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD010632-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010)." data-id="CD010632-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010)." data-id="CD010632-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-001" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-001.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-001.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-002" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-002.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Landau 2010 ADNI study)." data-id="CD010632-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-002.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Landau 2010 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-003" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-003.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Schmand 2012 ADNI study)." data-id="CD010632-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-003.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Schmand 2012 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-004" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-004.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-004.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-005" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-005.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-005.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-006" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-006.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study)." data-id="CD010632-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-006.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-006.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-007" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-007.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010)." data-id="CD010632-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-007.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 7</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-007.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010632-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/urn:x-wiley:14651858:media:CD010632:CD010632-TST-008" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_t/tCD010632-TST-008.xxx" target="_blank"><b></b></a></p> </div><img alt="18FFDG‐PET Conversion from MCI to All dementia (with Reader 2 Pardo 2010)." data-id="CD010632-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-008.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 8</div> <div class="figure-caption"> <p><sup>18F</sup>FDG‐PET Conversion from MCI to All dementia (with Reader 2 Pardo 2010). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/media/CDSR/CD010632/image_n/nCD010632-TST-008.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010632-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Summary of findings table</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>What is the diagnostic accuracy of ¹⁸F‐FDG PET biomarker for detecting Alzheimer's disease, and predicting progression to dementia, in people with mild cognitive impairment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Descriptive</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Participant population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Participants diagnosed with MCI at baseline using any of the Petersen criteria or CDR = 0.5 or any 16 definitions included by <a href="./references#CD010632-bbs2-0091" title="MatthewsFE , StephanB , McKeithIG , BondJ , BrayneC . Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008; Vol. 56, issue 8:1424‐33. [1532‐5415] ">Matthews 2008</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Sources of referral</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0001"> <li> <p>GP surgeries or specialists or other institutions or self referral (n = 3)</p> </li> <li> <p>Not reported (n = 13)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>MCI criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0002"> <li> <p>Petersen criteria (with or without CDR = 0.5 criterion) (n = 14)</p> </li> <li> <p>AAMI criteria (n = 1)</p> </li> <li> <p>Global Deterioration Scale (n = 1)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Sampling procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0003"> <li> <p>Consecutive or random (n = 3)</p> </li> <li> <p>Unclear (n = 13)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Prior testing</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The only testing prior to performing the ¹⁸F‐FDG PET scans was the application of diagnostic criteria for identifying participants with MCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Sources of recruitment</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0004"> <li> <p>University departments, clinics or research centres (n = 7)</p> </li> <li> <p>Multicentre, not specified (n = 3)</p> </li> <li> <p>Outpatient memory clinic or outpatients (sources not specified) or Geriatric, Research, Education and Medical centre (n = 3) </p> </li> <li> <p>Not reported (n = 3)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Index tests</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>¹⁸F‐FDG PET</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Threshold prespecified at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0005"> <li> <p>Yes (n = 6)</p> </li> <li> <p>No (n = 10)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>PET scan interpretation</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p> <ul id="CD010632-list-0006"> <li> <p>Combination of visual inspection and quantitative (rCGMr) evaluation (n = 12)</p> </li> <li> <p>Only visual PET scan interpretation (n = 4)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Threshold</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Almost all included studies referred to ratios of cerebral glucose metabolism (rCGMr) and not to absolute numbers. They used a range of different thresholds (different brain regions studied as potential AD areas as well as different scaling). </p> <p>Most of the studies (12/16) performed PET analysis based on the combination of visual analysis (qualitative) and rCGMr estimations (quantitative). The rest (4/16) only referred to visual PET inspections (qualitative‐only analysis). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>¹⁸F‐FDG hypometabolism regions</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Authors used brain regions that are expected to be affected by AD. In these terms, all studies involved temporo‐parietal lobes and most of them (12/16) also included the posterior cingulate metabolism in their assessment. 7 studies also involved part of the frontal lobes in their evaluations. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Reference standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>For Alzheimer’s disease dementia:</p> <p> <ul id="CD010632-list-0007"> <li> <p>NINCDS‐ADRDA (n = 13)</p> </li> <li> <p>Other (n = 3)</p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Target condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Conversion from MCI to Alzheimer’s disease dementia or any other forms of dementia.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Prospectively well‐defined cohorts with any accepted definition of MCI (as above). 16 included studies (<b>N=697</b> participants) were identified. 3 studies included ADNI participants. Number included in analysis was <b>421</b> from 14 studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Quality concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>QUADAS‐2 scoring was challenging due to insufficient details. Poor reporting about sampling procedure led mainly to unclear risk of bias or contributed to high risk of bias in the participant selection domain. Although the reference standard was regarded as adequate to correctly classify the target condition, poor reporting on blinding of dementia assessors determined unclear risk of bias in the reference domain in most of the included studies. According to the assessment of Index test domain, more than 50% of studies were of poor methodological quality due to lack of prespecified threshold. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Limitations</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Limited investigation of heterogeneity due to insufficient number of studies. Lack of common thresholds. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cases/ Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Median specificity from included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)<sup>1</sup> at median specificity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Consequences in a cohort of 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median percentage converting % (range)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missed cases<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over</p> <p>Diagnosed<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Alzheimer's disease dementia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>¹⁸F‐FDG PET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150/421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (54 to 90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5 (22 ‐ 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Key feature of the results:</b> </p> <p>The results of the included studies show a great deal of heterogeneity, encompassing both values which would render the technology “useless” and some which indicate a valuable diagnostic tool. The sensitivity values ranged from 25% to 100%, while the specificity values ranged from 29% to 100%. The values for both sensitivity and specificity were mainly over 80% in 7 included studies. In the remaining 7 studies those values were less than 80% or a sensitivity value higher than 80% was accompanied by a very low specificity value and vice versa. </p> <p><b>Investigation of heterogeneity:</b> </p> <p>We investigated the effects of interpretation of PET scan (combination of visual inspection and quantitative rCGMr evaluation versus those that used visual interpretation only) and use of the prespecified threshold on the test results. There was no impact on our findings. </p> <p>The remaining planned investigations (e.g. the effect of spectrum of participants, referral centres, ¹⁸F‐FDG reduction brain regions, inadequate blinding or loss to follow‐up) were not possible due to the limited number of studies available for each analysis. We conducted sensitivity analyses for type of clinical diagnosis for MCI and for type of reference standard. There was no impact on our findings. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Conclusions:</b> </p> <p>Given the considerable variability and specificity values, the heterogeneity in the conduct and interpretation of the test, and lack of defined thresholds for determination of test positivity in the included studies, the current evidence does not support the routine use of ¹⁸F‐FDG PET scan in clinical practice. ¹⁸F‐FDG PET scan is a high‐cost investigation, and it is therefore important to clearly demonstrate its accuracy and to standardise the process of ¹⁸F‐FDG PET diagnostic modality prior to its being widely used. Future studies with more uniform approaches to thresholds, analysis and study conduct may provide a more homogeneous estimate than the one that has been available from the included studies we have identified. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Meta‐analytic estimate of sensitivity derived from the HSROC model at a fixed value of specificity. We did not compute summary estimates of sensitivity and specificity because the studies that contributed to the estimation of the summary ROC curve used various thresholds. </p> <p><sup>2</sup> We derived the median proportion converting (reported as a percentage) and range using all the studies included in the analysis for each target condition. </p> <p><sup>3</sup> We computed missed and over‐diagnosed numbers using the median proportion converting to each target condition. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Summary of findings table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010632-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classification systems for describing mild cognitive impairment according to Matthews 2008</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>System</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Impairment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Age‐related cognitive change</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ACMI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age‐consistent memory</p> <p>impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memories aging in accord with normative expectations; individual aged 50 to 79 and reports a decline in memory verified using objective memory testing performance (within ± 1 standard deviation of aged norms on 75% of tests (memory) administered); preserved general functioning. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ARCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age‐related cognitive decline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Objectively identified decline in memory and cognitive functioning considered to be a normal consequence of aging. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Category systems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMC</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective memory complaint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐reported decline in memory.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mini‐Mental State Examination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Classification based on MMSE cut‐offs (maximum score 30). 'Normal' defined as a score from 27 to 30; MCI defined as a score from 22 to 26; and 'impaired' defined as a score &lt; 21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Pathological decline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MNCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild neurocognitive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impairment resulting from a general medical condition; reported decline in cognitive functioning supported by formal testing; deficits observed in at least 2 areas of cognitive functioning; interference in social, occupational, or other areas of functioning. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIND</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive impairment no dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive impairment in one or more domains (including memory and non‐memory domains) that can have a variety of aetiologies. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benign senescent</p> <p>Forgetfulness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impairment in remote memory and intact recent memory; awareness of the impairment and use of compensatory </p> <p>strategies.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AAMI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age‐associated memory impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective and objective memory loss associated with normal aging; individual aged 50 and older and shows adequate intellectual function (i.e. without dementia). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimal dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cognitive impairment in memory and minor and variable errors in orientation; no evidence of impaired occupational or social functioning; self care unimpaired. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limited cognitive disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported decline in memory with use of compensatory strategies; occasional forgetfulness (e.g. names, places); 1 or 2 errors on cognitive (memory) testing. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Questionable dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impaired memory and non‐memory test performance; no significant activity of daily living or instrumental activity of daily living interference. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AACD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age‐associated cognitive decline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Self‐ or informant report of cognitive decline (gradual and present for 6 months); objective difficulties in any of the following domains: learning and memory, attention and concentration, thinking, language, and visuospatial functioning </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MCD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild cognitive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decline in cognitive performance, including memory impairment and learning or concentration difficulties; complaint confirmed by cognitive tests; may precede, accompany, or follow a wide variety of infections or physical disorders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Mayo Clinic Criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N‐MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐amnestic mild cognitive impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjective memory complaint; normal general cognitive function; normal range of activities of daily living; objective impairment in 1 or more domains other than memory. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>A‐MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amnestic mild cognitive impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective memory complaint; normal general cognitive function; normal range of activities of daily living; impaired memory performance; normal non‐memory test performance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>M‐MCI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple mild cognitive impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subjective memory complaint; normal general cognitive function; normal range of activities of daily living; impaired memory and nonmemory test performance </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classification systems for describing mild cognitive impairment according to Matthews 2008</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010632-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for the diagnosis of mild cognitive impairment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Petersen 1999</b> </p> <p> <ol id="CD010632-list-0009"> <li> <p>Memory complaint, preferably corroborated by an informant.</p> </li> <li> <p>Impaired memory function compared for age and education.</p> </li> <li> <p>Preserved general cognitive function.</p> </li> <li> <p>Intact activities of daily living.</p> </li> <li> <p>Not demented.</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Petersen 2004</b> </p> <p> </p> <p>4 subtypes of MCI were identified:</p> <p> <ol id="CD010632-list-0010"> <li> <p>Amnesic mild cognitive impairment, single domain – isolated memory impairment of more than 1.0 SD compared with the age‐ and education‐specific norms, and no difficulty in any other area of cognitive functioning. </p> </li> <li> <p>Amnesic mild cognitive impairment, multiple domain – 2 or more cognitive domains are impaired, 1 of which is memory impairment (impairment of more than 1.0 SD below the mean of the respective age‐ and education‐matched population). </p> </li> <li> <p>Non‐amnesic mild cognitive impairment, single domain – impairment in a single domain other than memory of more than 1.0 SD. </p> </li> <li> <p>Non‐amnesic mild cognitive impairment, multiple domains – impairments in 2 or more domains of more than 1.0 SD but no memory impairment. </p> </li> </ol> </p> <p> </p> <p>All 4 subtypes of mild cognitive impairment also have to meet the following criteria:</p> <p>a)  the presence of a complaint about memory – participants or informants (or both) reporting memory impairment. </p> <p>b)  intact ability to perform activities of daily living – forgetfulness not compromising overall functional ability; impairment owing to physical disease not sufficient for exclusion. </p> <p>c)   absence of dementia – assessed by DSM–IV criteria.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morris 1993</b> </p> <p> </p> <p>Clinical Dementia Rating (CDR) is a scale used to classify patients along a continuum from normal aging through Alzheimer’s disease. This scale describes a continuum from normal (CDR 0) through questionable dementia or MCI (CDR 0.5) to mild (CDR 1), moderate (CDR 2), and severe (CDR 3) dementia. </p> <p> </p> <p>Patient's cognitive and functional performances are assessed in 6 areas: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Scores in each of these areas are combined to obtain the total score. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p>MCI: mild cognitive impairment</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for the diagnosis of mild cognitive impairment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010632-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Demographic and participant characteristics of participants included in analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N / n (included in analysis)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age converters (non‐converters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Gender</b> </p> <p><b> (M %) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MMSE score</b> </p> <p><b> converters (non‐converters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> APOE Ɛ4 carrier (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MCI diagnostic criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sampling</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sources of referral</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sources of recruitment</b> </p> <p><b> (setting)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. "><b>Anchisi 2005</b> </a> </p> <p><b>(Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67/48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.1 ± 73.9</p> <p>(65.0 ± 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (52.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6 ± 1.7</p> <p>(28.4 ± 1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0108" title="PattersonJC , LilienDL , TakalkarA , PinkstonJB . Early detection of brain pathology suggestive of early AD using objective evaluation of FDG‐PET scans. International Journal of Alzheimer's Disease2010; Vol. 2011:ii. 946590. [DOI: 10.4061/2011/946590] ">Patterson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> <p>(email from the author on 22nd October 2013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP surgeries</p> <p>(email from the author on 22nd October 2013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients from</p> <p>4 University Departments (Milan, Brescia, Cologne and Dresden)</p> <p>(email on 22nd October 2013)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. "><b>Arnáiz 2001</b> </a> </p> <p><b>(Sweden)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9 ± 8.3</p> <p>(60.1 ± 8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (60.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.7 ± 1.8</p> <p>(27.2 ± 2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global Deterioration Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geriatric University clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. "><b>Berent 1999</b> </a> </p> <p><b>(USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 ± 5.5</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (65.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0 ± 1.9</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AAMI</p> <p>criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive disorders University clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chételat 2003</b> </p> <p><b> (France)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.0 ± 5.1</p> <p>(67.8 ± 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (45.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.3 ± 1.0</p> <p>(27.8 ± 1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0110" title="PetersenRC , DoodyR , KurzA , MohsRC , MorrisJC , RabinsPV , et al. Current concepts in mild cognitive impairment. Archives of Neurology2001; Vol. 58, issue 12:1985‐92. ">Petersen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. "><b>Clerici 2009</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.2 ± 6.9</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (33.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2 ± 1.7</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0112" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004; Vol. 256, issue 3:183‐94. [1365‐2796] ">Petersen 2004</a> and CDR = 0.5 criteria </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP surgeries or specialists (85%) or self referral (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Centre for Research and Treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. "><b>Drzezga 2005</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.7 ± 4.7</p> <p>(67.6 ± 2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (46.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.9 ± 2.1</p> <p>(27.6 ± 1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (56.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> and CDR = 0.5 criteria </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP surgeries or</p> <p>specialists or other institutions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University Research Unit</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. "><b>Fellgiebel 2007</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.5 ± 7.9</p> <p>(68.8 ± 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (56.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3 ± 1.5</p> <p>(27.3 ± 1.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>University memory clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. "><b>Galluzzi 2010</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.0 ± 7.1</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (41.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.1 ± 1.8</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (38.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consecutive sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient memory clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. "><b>Herholz 2011</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0 ± 7.6</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (70.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2671 ± 1.6</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0114" title="PetersenRC , AisenPS , BeckettLA , DonohueMC , GamstAC , HarveyDJ , et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology2010;74(3):201‐9. ">Petersen 2010</a> &amp; </p> <p>CDR = 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre (not specified)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. "><b>Landau 2010</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.3 ± 7.5</p> <p>(78.0 ± 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (65.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.4 ± 1.7</p> <p>(27.3 ± 1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (29.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Petersen 2010 &amp;</p> <p>CDR=0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter (not specified)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. "><b>Mosconi 2004</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0 ± 4.0</p> <p>(63.0 ± 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (45.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.9 ± 1.7</p> <p>(28.1 ± 1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (43.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0114" title="PetersenRC , AisenPS , BeckettLA , DonohueMC , GamstAC , HarveyDJ , et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology2010;74(3):201‐9. ">Petersen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. "><b>Nobili 2008</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3 ± 4.8</p> <p>(74.6 ± 5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (39.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0 ± 4.0</p> <p>(63.0 ± 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on all MCI included in analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0112" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004; Vol. 256, issue 3:183‐94. [1365‐2796] ">Petersen 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. "><b>Ossenkoppele 2012a</b> </a> </p> <p><b> (Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.0 ± 7.0</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (75%)</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0 ± 7.6</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (66.7)</p> <p>Sample analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. "><b>Ossenkoppele 2012b</b> </a> </p> <p><b> (Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.0 ± 9.0</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (30.4)</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0 ± 7.6</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0110" title="PetersenRC , DoodyR , KurzA , MohsRC , MorrisJC , RabinsPV , et al. Current concepts in mild cognitive impairment. Archives of Neurology2001; Vol. 58, issue 12:1985‐92. ">Petersen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient University memory clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a> </p> <p><b> (USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/18 Reader 1</p> <p>19/19 Reader 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 80.0 (range 54 ‐ 83)</p> <p>Total sample</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0109" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999; Vol. 56, issue 3:303‐8. ">Petersen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Geriatric, Research, Education and Medical Centre</p> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. "><b>Schmand 2012</b> </a> </p> <p><b> (Netherlands)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89/89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported on the sample with ¹⁸F‐FDG scan (N = 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0114" title="PetersenRC , AisenPS , BeckettLA , DonohueMC , GamstAC , HarveyDJ , et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology2010;74(3):201‐9. ">Petersen 2010</a> &amp; </p> <p>CDR = 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre (not specified)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>ADNI: Alzheimer's Disease neuroimaging initiative</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Demographic and participant characteristics of participants included in analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010632-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Index test and numbers of converters to Alzheimer’s disease dementia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Threshold</b> </p> <p><b> (prespecified</b> </p> <p><b> Yes/No)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Image scaling</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Discriminating brain area</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Image analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time between FDG injection and PET acquisition (min)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>¹⁸F‐FDG dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of ¹⁸F‐FDG positive</b> </p> <p><b> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of converters (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of follow‐up</b> </p> <p><b> Mean (months) / Maximum (years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. "><b>Anchisi 2005</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of temporo‐parietal and posterior cingulate of 1.138</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Regional sensorimotor</p> <p>FDG uptake ratio (p 1730)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bilateral parietal and posterior cingulate cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (40)</p> <p>(calculated in RevMan5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 12 months</p> <p>Range: 12 ‐ 27 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. "><b>Arnáiz 2001</b> </a> </p> <p><b>(Sweden)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of left temporo‐parietal region 13 mm above the basal ganglia</p> <p>(Model I)</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensorimotor</p> <p>area of the cortex 26 mm above the level of the basal ganglia (p 852)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporo‐parietal cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> <p>(<a href="./references#CD010632-bbs2-0077" title="HerholzK , NordbergA , SalmonE , PeraniD , KesslerJ , MielkeR , et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders1999;10(6):494–504. ">Herholz 1999</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (40)</p> <p>(calculated in RevMan5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. "><b>Berent 1999</b> </a> </p> <p><b> (USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of</p> <p>diagnostic index based on Z‐scores of the parietal cortex</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thalamus (p 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, temporal, parietal and occipital regions normalised to the thalamus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3D‐SSP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. "><b>Chételat 2003</b> </a> </p> <p><b> (France)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc at Z‐score of &gt; 3.09</p> <p>Thresholding was set at 80% of whole brain mean of control subjects</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FDG uptake normalised by and adjusted to the person’s global uptake (p 1375)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right temporo‐parietal and posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (41)</p> <p>right temporo‐parietal region</p> <p>8 (47.0) posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. "><b>Clerici 2009</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc</p> <p>lower than the control group corresponding to a P value &lt; 0.01 level)</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global counts were normalised by proportional scaling to remove confounding effects due to global changes </p> <p>(<a href="./references#CD010632-bbs2-0066" title="DelSoleA , ClericiF , ChitiA , LecchiM , MarianiC , MagioreL , et al. Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG‐PET study. European Journal of Nuclear Medicine and Molecular Imaging2008;35(7):1357‐66. ">Del Sole 2008</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Posterior gyrus cingulate and bilateral inferior frontal cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM(t)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185‐370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (88.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 years aMCI group.</p> <p>3 years snaMCI group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. "><b>Drzezga 2005</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc at</p> <p>Z‐score of &gt; 1.64 (1‐tail) corresponding to a P value of 0.05 (1‐tail)</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orbitofrontal, prefrontal, premotor, central, parietal superior and inferior, occipital, temporal anterior, temporal posterior and posterior cingulate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3D‐SSP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 ± 2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. "><b>Fellgiebel 2007</b> </a> </p> <p><b> (Germany)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc at</p> <p>significantly decreased Z‐score &gt; 2 in more than 50 adjacent pixels</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensorimotor</p> <p>area of the cortex (transaxial images parallel to the intercomissural line)</p> <p>(<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parietal mesial or posterior cingulate and temporal regions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> <p>(<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 MBq (<a href="./references#CD010632-bbs2-0071" title="FellgiebelA , SiessmeierT , ScheurichA , WintererG , BartensteinP , SchmidtLG , atal . Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry2004;56(4):279‐83. ">Fellgiebel 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 ± 9.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. "><b>Galluzzi 2010</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of</p> <p>t sum &gt; 11.090 (email from the author)</p> <p>(<a href="./references#CD010632-bbs2-0078" title="HerholzK , SalmonE , PeraniD , BaronJ , HolthoffV , FrölichL , et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage2002; Vol. 17, issue 1:302‐16. [1053‐8119] ">Herholz 2002</a>) </p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporo‐parietal, hippocampus and posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6.6 ± 9.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. "><b>Herholz 2011</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of</p> <p>t sum &gt; 11.090</p> <p>(<a href="./references#CD010632-bbs2-0078" title="HerholzK , SalmonE , PeraniD , BaronJ , HolthoffV , FrölichL , et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage2002; Vol. 17, issue 1:302‐16. [1053‐8119] ">Herholz 2002</a>) </p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporal and parietal lobes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PALZ (PMOD software)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 ‐ 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. "><b>Landau 2010</b> </a> </p> <p><b> (USA)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGMglc of 1.21</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellar vermis and pons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROI interest were study‐independent, frequently associated with decline in AD and MCI. No further details. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 ‐ 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 ± 0.4 years Range: 2 ‐ 3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. "><b>Mosconi 2004</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCMRglc significantly reduced in certain cerebral areas with emphasis on the inferior parietal lobule (IPL). </p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Precuneus, anterior and posterior cingulate, inferior parietal lobe, superior, middle and inferior frontal gyrus, on both hemispheres </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPM99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 ± 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 ‐ 370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (10.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 ± 0.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. "><b>Nobili 2008</b> </a> </p> <p><b> (Italy)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection</p> <p>rCGMglc threshold not reported</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cortex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 VROI in each hemisphere</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Computerized Brain Atlas (CBA;</p> <p>Applied Medical Imaging©, Uppsala, Sweden)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.1 ± 10.9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. "><b>Ossenkoppele 2012a</b> </a> </p> <p><b>(Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection and SUVr of ROIs (threshold not reported) (No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellar grey matter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, parietal and latero‐temporal and medial temporal lobes and posterior cingulate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PMOD Alzheimer discrimination tool (PALZ)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 ‐ 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 ± 17 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>Range: 2 ‐ 4 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. "><b>Ossenkoppele 2012b</b> </a> </p> <p><b>(Netherlands)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection and SUVr of ROIs (threshold not reported) (No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebellar grey matter (p 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, parietal, occipital, and latero‐temporal and medial temporal lobes and posterior cingulate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PMOD Alzheimer discrimination tool (PALZ)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45‐60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 MBq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a> </p> <p><b> (USA)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual inspection</p> <p>Hypomethabolism if &lt; 50% of the cubes had the label MCI or normal</p> <p>(Only SVM analysis used thresholds)</p> <p>(No)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PET scans were adjusted to a whole‐brain mean activity and stereotactically normalised by using Neurostat (p 328) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frontal, parietal, occipital, and latero‐temporal and medial temporal lobes and posterior cingulate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SVM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mCi/70 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reader 1:</p> <p>6(32)</p> <p>Reader 2:</p> <p>10 (53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (44)</p> <p>9 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. "><b>Schmand 2012</b> </a> </p> <p><b> (Netherlands)</b> </p> <p><b> ADNI participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCGM value of &lt; 1.20</p> <p>(Email from the author)</p> <p>(Yes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Right and left angular gyrus, bilateral posterior cingulate gyrus and left middle/inferior temporal gyrus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SPSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not</p> <p>reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 ± 0.9</p> <p>Range: 0.5 ‐ 4.6 years</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>ADNI: Alzheimer's Disease neuroimaging initiative<br/> RevMan5: Review Manager 5 software<br/> SUVr: standardised uptake value ratio<br/> VROI: volumetric region of interest </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Index test and numbers of converters to Alzheimer’s disease dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010632-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of test accuracy at study level for conversion to Alzheimer’s disease dementia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Studies included in meta‐analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participants (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sensitivity (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Specificity (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> % of MCI with ¹⁸F‐FDG PET positivity </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0001" title="AnchisiD , BorroniB , FranceschiM , KerroucheN , KalbeE , KerroucheN , atal . Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology2005;62(11):1728‐33. "><b>Anchisi 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0002" title="ArnáizE , JelicV , AlmkvistO , WahlundL‐O , WinbaldB , ValindS , et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport2001;12(4):851‐5. "><b>Arnáiz 2001</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0003" title="BerentS , GiordaniB , FosterN , MinoshimaS , Lajiness‐O'NeillR , KoeppeR , et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research1999;33(1):7‐16. "><b>Berent 1999</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. "><b>Chételat 2003</b> </a> </p> <p><b>(temporo‐parietal brain region)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0005" title="ClericiF . Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging2009;53(6):646‐57. "><b>Clerici 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0006" title="DrzezgaA , GrimmerT , RimenschneiderM , LautenschlagerN , SiebnerH , Alexopoulus , et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine2005;46(10):1625‐32. "><b>Drzezga 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0007" title="FellgiebelA , ScheurichA , BartensteinP , MüllerMJ . FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research2007;155(2):167‐71. "><b>Fellgiebel 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0008" title="GalluzziS , Geroldi , C , GhidoniR , PagheraB , AmicucciB , BonettiM , et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology2010;257(12):2004–14. "><b>Galluzzi 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0009" title="HerholzK , WestwoodS , HaenseC , DunnG . Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine2011;52(8):1218‐26. "><b>Herholz 2011</b> </a><b> (ADNI study)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0011" title="MosconiL , PeraniD , SorbiS , HerholzK , NacmiasB , HolthoffV , et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology2004;63(12):2332‐40. "><b>Mosconi 2004</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0012" title="NobiliF , SalmasoD , MorbelliS , GirtlerN , PiccardoA , BrugnoloA , et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging2008;35(12):2191‐202. "><b>Nobili 2008</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0013" title="OssenkoppeleR , TolboomN , Foster‐DingleyJC , AdriaanseSF , BoellaardR , YaqubM , et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging2012;39(6):990‐1000. "><b>Ossenkoppele 2012a</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0014" title="OssenkoppeleR , PrinsN , PijnenburgYAL , LemstraAW , Van derFlierWM , AdriaanseSF , et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's &amp; Dementia2012;9(4):414‐21. "><b>Ossenkoppele 2012b</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a><b>(Reader 1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> Studies included only in descriptive analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0004" title="ChételatG , DesgrangesB , De laSayetteV , ViadreF , EustacheF , BaronJC . Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology2003;60(8):1374‐7. "><b>Chételat 2003</b> </a> </p> <p><b>(posterior cingulate brain region)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0010" title="LandauSM , HarveyD , MadisonCM , ReimanEM , FosterNL , AisenPS , et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology2010;75(3):230‐8. "><b>Landau 2010</b> </a><b> (ADNI study)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0015" title="PardoJV , LeeJT , KuskowskiMA , MunchKR , CarlisJV , SheikhSA , et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's &amp; Dementia2010;6(4):326‐33. "><b>Pardo 2010</b> </a><b> (Reader 2)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010632-bbs2-0016" title="SchmandB , EikelenboomP , vanGoolWA , Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease2012;29(3):641‐8. "><b>Schmand 2012</b> </a><b> (ADNI study)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ADNI: Alzheimer's Disease neuroimaging initiative</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of test accuracy at study level for conversion to Alzheimer’s disease dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/full#CD010632-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010632-tbl-0007"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 <sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 <sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Landau 2010 ADNI study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 <sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Schmand 2012 ADNI study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 <sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 <sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 <sup>18F</sup>FDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">7 <sup>18F</sup>FDG‐PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">8 <sup>18F</sup>FDG‐PET Conversion from MCI to All dementia (with Reader 2 Pardo 2010) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010632.pub2/references#CD010632-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010632.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010632-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010632-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010632-note-0002">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010632\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010632\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010632\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010632\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010632\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010632.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010632.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010632.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010632.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010632.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720042118"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010632.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720042121"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010632.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df77e6d259368',t:'MTc0MDcyMDA0Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 